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Abstract 
 
Effects of Short Term Dietary Nitrate Supplementation on Energy 
Metabolism during Isokinetic Knee Muscle Contractions 
 
Kyoungrae Kim, MS KIN 
The University of Texas at Austin, 2014 
 
Supervisor: Robert M. Brothers 
 
The purpose of this study was to investigate whether 3 days of dietary nitrate 
supplementation has positive effects on exercise performance and energy metabolism at 
rest and during strenuous knee exercise, and exercise recovery. The experimental 
protocol was a double blind, placebo-controlled, two-period, and within-subjects design. 
Fourteen healthy nonsmoking males (22.71 ± 0.72yr, 72.93 ± 2.35kg, and 47.67 ± 1.56 
ml/kg/min VO2max) participated in the study. Two supplements (nitrate lozenge; NO-L or 
placebo; PLA) were orally administrated randomly at 48 and 24 hours before each trial 
day and again 40 minutes before each exercise trial. Total work, peak torque, and 
respiratory gases were automatically collected during repeated knee extensions/flexions 
(isokinetic concentric contractions with dominant leg; 4 sets of 28 repetitions at 180°/sec 
with 30 sec rest intervals) and recovery (6 contractions of 1 repetition maximum with 120 
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sec between contractions). For these results, peak torque, rate of fatigue, work efficiency, 
and rate of recovery were calculated. Blood specimens were collected at rest before and 
after the treatment, post exercise, and end of recovery to track the changes in blood 
glucose and lactate concentrations. There was a significant inverse correlation for total 
work during knee extension exercise and oxygen consumption (PLA: r = -.560 and NO-L: 
r = -.546; p < .01, respectively). During the exercise, RER was significantly higher for 
PLA compared with NO-L (PLA: 1.42 ± 0.02 vs. NO-L: 1.38 ± 0.02: p = .03). Work 
within each set and total work performed were higher for NO-L, but these differences 
were not significant. However, NO-L enhanced exercise efficiency by 3.3% when 
compared with PLA (PLA: 2497.5 ± 134.56 ft-lb/L/min vs. NO-L: 2578.7 ± 132.24 ft-
lb/L/min; p = .05). Extensor peak torque recovery rate slope was not significant, but 
meaningfully faster for NO-L (PLA: 2.39 ± 0.52% vs. NO-L: 3.06 ± 0.54%; p = .09) and 
significant interaction effect (p = .02) was found during recovery contractions, especially 
from contractions 2 to 3 (p = .03). It is also worth noting that differences in time to peak 
torque during knee extension exercise for NO-L and PLA approached significances (PLA: 
0.213 ± 0.01 sec vs. NO-L: 0.200 ± 0.01 sec; p = .08). The results suggest that 3 days of 
dietary nitrate supplementation improves rate of exercise recovery and enhances work 
efficiency during vigorous resistance exercise. 
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INTRODUCTION 
For those who must prove their performance in competitive sport events, it is important 
to have a well-organized daily training program. It is also important for those who wish to 
challenge their physical limits. The nutritional supplement market has been developed and 
various ergogenic aids covering physical to psychological effectiveness have been introduced to 
the fields (Kreider et al., 2010).  
Individual supplements affect exercise performance through supplement-specific 
mechanisms in the human body. For example, caffeine supplementation improves endurance 
performance by enhancing free fatty acid utilization (Ivy et al., 1979), while creatine 
monohydrate supplementation is mostly used in strength training with the purpose of promoting 
anaerobic capacity by directly increasing high phosphate energy stores (Jäger et al., 2011).  
There is a rising supplement, inorganic dietary nitrate, which is a potent exogenous 
source of nitric oxide (NO) (McKnight et al., 1999). The key function of NO in the body is to 
relax smooth muscle and expand blood vessels and thus increase blood flow (Pearson & 
Vanhoutte, 1993). It is now well known that NO also increases the ATP to oxygen (P/O) ratio in 
the mitochondria by reducing the leakage of protons by reducing expression of uncoupling 
protein 3 (UCP3) and adenine nucleotide translocator (ANT) (Larsen et al., 2011A). In addition, 
Bailey et al. (2010) suggested NO reduced the ATP turnover rate during muscle contraction, thus 
increasing exercise efficiency during repeated knee muscle extension contractions. Based on the 
knowledge of prior studies, many exercise scientists have focused on dietary nitrate 
supplementation, which includes various types of treatments such as sodium nitrate, sodium 
nitrite, and beetroot juice (Bescós et al., 2012B). Studies continuously support the claim that 
augmenting NO bioavailability in the blood after the intake of nitrate supplements results in 
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positive effects on blood pressure (Vanhatalo et al., 2011), the oxygen cost of exercise (Cermak 
et al., 2012A), and the exercise performance (Wilkerson et al., 2012 & Fulford et al., 2013). 
 
The Need for Research 
Most of the knowledge established in support of dietary nitrate supplementation has been 
based on sub-maximal (Larsen et al., 2007 & Bailey et al., 2009) or endurance exercise 
(Wilkerson et al., 2012 & Cermak et al., 2012) and thus there is a lack of information on how 
dietary nitrate supplementation affects performance and metabolism during resistance exercise 
on high intensity short duration, intermittent maximal intensity exercise. Blood nitrate and nitrite 
levels reach peak values approximately 1.5 hours to 3 hours, respectively after acute nitrate 
supplementation (Webb et al., 2008 & Wylie et al., 2013A) and thus most studies that report 
positive effects were performed at the nitrite peak time, which means 2.5 to 3 hours after 
supplement consumption (Lansley et al., 2011 & Bescós et al., 2012). Short-term nitrate 
supplementation studies, on the other hand, have shown that 2 to 5 days administration prior to 
testing significantly increases the plasma nitrite level, but actual exercise tests were conducted at 
least 2 to 2.5 hour after last nitrate load. Considering the interval between supplementation and 
exercise, this approach is inconvenient for the athlete. Based on these limitations, a new nitrate 
lozenge (NO-L) that generates NO rapidly was investigated. NO-L contains a natural source of 
nitrate and nitrite that can be converted to NO in the oral cavity. In our previous study about 
acute NO supplementation, we found significant improvement in cycling time trial performance 
without a difference in oxidative phosphorylation efficiency. Since the additional NO effects on 
metabolic efficiency have been typically found after 3~6 days of nitrate administration, we took 
this into consideration when administering the NO-L.  
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Purpose 
The purpose of this study was to determine whether 3 days of NO-L supplementation 
advances the peak blood NO level and timing with positive effects on exercise performance and 
energy metabolism during intense repeated isokinetic knee muscle contractions. 
 
Hypotheses 
We hypothesized that short-term NO-L supplementation would 
1. Improve hemodynamic indicators throughout the trials  
2. Increase total work or reduce oxygen cost and thus improve work efficiency 
3. Decrease rate of fatigue and increase rate of leg force recovery  
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METHODS 
Before recruiting subjects, the present study was approved by The Institutional Review 
Board (IRB) of the University of Texas at Austin and the study protocol was planned as a double 
blind, randomized, placebo-controlled, and within-subjects design (Appendix C1). 
 
Subjects 
As study subjects, fourteen healthy nonsmoking male volunteers between 20 and 28 years 
old were recruited from the Austin, Texas area. The 50
th
 percentile of VO2max value 
(42.5ml/kg/min) based on sex and age was used as the criterion to screen out unfit subjects. 
During the period of the study (Below), each participant was required not to be involved in any 
other studies and not to intake any other supplements except NO-L and PLA. 
 
Time Period of the Study 
Experiment period for each subject was about 1 month and consist of 4 visits to the 
laboratory. From visit 2, each visit was spaced 1 week apart (Appendix C2).  
Visit 1 
(Screening) 
 
Visit 2 
(Familiarization) 
 
 
1 week 
 
Visit 3 
(Trial one) 
 
 
1 week 
 
Visit 4 
(Trial two) 
 
 
 
 
Screening Test 
After signing The Informed Consent Form (ICF) and completing the health screener, 
each subject’s basic information of resting blood pressure, height, weight, and dominant leg was 
collected. Potential subjects then completed a VO2max test on a computer-controlled cycle 
ergometer (Velotron, Racer Mate, USA). The protocol for VO2maxtest (Appendix B1) consisted 
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of a warm-up followed by 1min stages of increasing difficulty until fatigue. The subject breathed 
expired gases into a mixing chamber for analysis of pulmonary ventilation (VE), oxygen 
consumption (VO2), and carbon dioxide production (VCO2). Inspired gases were collected and 
analyzed using a computer-controlled metabolic cart (Pravo Medics, True One 2400, USA). The 
criteria used to establish VO2max were a plateau in VO2 with increasing exercise intensity, 
respiratory exchange ratio (RER) > 1.10, rated perceived exertion (RPE) > 17 on the Borg scale, 
and pedaling of minimum revolutions per minute (RPM) < 60. Afterward the subjects were given 
a cool-down (5 min) period and rest interval (20~30 min) to recover from the VO2max test prior to 
starting the knee exercise (isokinetic concentric contraction dominant leg only) practice. Proper 
explanation and feedback about the position and kicks were given during the practice. From this 
first visit, identical knee exercise protocol [(exercise protocol; 4 sets of 28 repetitions at 180°/sec 
angular velocity of 90° range of motion (ROM) with 30 seconds interval between sets) and 
(recovery protocol; 6 contractions of 1 repetition maximum at 180°/sec angular velocity of 90° 
ROM with 120 seconds interval between contractions)] was used in order to minimize the 
learning effect (Appendix B2).  
 
Familiarization  
Procedure for the familiarization was identical with the experimental trials (Appendix B3) 
except that subjects did not receive a supplement and no blood samples were drawn. During 
familiarization, all subjects were required to have a catheter inserted into their forearm vein so 
that the risk of an uncomfortable feeling and fainting should be minimized during the 
experimental trials. In addition, the investigator informed provided instruction on how to take the 
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study supplements (Appendix C4) and set the time of testing of each subject based on 
supplementation and blood sampling.  
 
Experimental Trials 
All subjects were required to consume a total three lozenges of NO-L or PLA two days 
before each trial (1 lozenge/day). A reminder email was sent 3 days before the trial to ensure 
compliance with supplementation guidelines, and provide general information and instructions. 
Two text messages were also followed 2 days and 1 day before the trial to monitor 
supplementation and to determine if subjects were complying with guidelines for daily activity. 
Once subjects arrived at the lab, questions about the information of drinking caffeine or 
alcohol and mouth washing were asked and body mass was measured. Drinking water was 
inhibited until to the end of the study. To check the fasting status, blood glucose was measured 
by using a finger prick and glucose meter (Life Scan, OneTouch Ultra, USA). If the fasting 
blood glucose was less than 100 mg/dl, a heart rate monitor (Cardio Sport, CE0434, Taiwan) was 
placed on the center of the subject’s chest. A catheter with extension tube was inserted into the 
subject’s forearm vein and flushed with 0.9% saline every 6-7min throughout the testing. A 5 ml 
blood sample was collected (BD1) and proper centrifugation and aliquot were followed by blood 
handling method (Appendix B7). The first blood pressure (BP1) (Omron Healthcare Inc, 
Bannockburn, USA) reading was then taken 2~3 min after resting. To collect pre-treatment basal 
metabolic gases subjects on the Biodex were required to maintain a relaxed static position during 
the 5 min measurement (Appendix B4.1). After the measurement of pre-treatment resting 
respiratory gases, subjects consumed the 3
rd 
lozenge and rested for 30 min without any activity. 
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At around 27 min, Subjects were positioned for the exercise protocol and 5 min post-treatment 
metabolic gases taken along with a second blood sample and a second blood pressure reading.  
Isokinetic knee exercise was initiated at 40 min post supplementation and then a third 
blood sample and blood pressure were collected during the 2 min interval between 4
th
 set and 
first recovery contraction. After the blood sample, 6 recovery contractions followed. During 
exercise (4 min) and recovery (12 min) phases, respiratory gas samples and heart rates were 
continuously collected and monitored (Appendix B4 and C5). To obtain the 5
th
 blood sample, 
subjects were reported to stop by the laboratory approximately 24 hours after the exercise and 
twelve out of fourteen subjects met the sampling schedule. 
 
Supplementation and Diet Control 
In the present study, NO-L and PLA were provided by Neogenis Lab (Austin, TX). NO-L 
contains 420mg of nitrate and nitrite blend and PLA was matched NO-L as a similar color and 
flavored non-caloric. Both supplements were formed as a lozenge type, which were able to be 
dissolved in the oral cavity with saliva within three minutes. Subjects received study products in 
random order approximately 1 week apart. Supplementation was designed for subjects to 
consume a total of 3 lozenges among which the first lozenge was taken two days, and the second 
lozenge one day prior to each experimental trial. The last lozenge was taken 40 minutes before 
the exercise test commenced. Only a member of our lab who had no direct contact with the 
subjects controlled randomization. To avoid an antibacterial effect on nitrate reduction in the 
mouth, the subjects were required to avoid using mouthwash during the whole time involved in 
the study. For two days prior to each exercise trial, subjects were required to eat similar types of 
foods and amounts around the same time, and to record foods consumed and exercises performed 
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on myfitnesspal.com. However, the type of foods consumed were not controlled could have 
contained a high nitrate concentrations. From the familiarization to the second trial, every test 
began with a 12-hour food and caffeine fast and with 24-hour vigorous exercise and alcohol 
abstention.  
 
Blood Handling 
Blood samples (5ml each) were collected at rest pre-treatment (BD1) and post-treatment 
(BD2), post exercise (BD3), and post recovery (BD4). Approximately, 2ml of 5ml of blood was 
transferred to a 12 × 17 test tube and then 1ml for analysis of NOx was mixed with 0.05ml of 
EDTA (24 mg/ml, pH 7.4) and 0.4 ml for lactate was mixed with 0.8ml of 10% perchloric acid 
(PCA). These micro-tubes were centrifuged for 15 minutes at 1,700 RCF (Eppendorf AG, 
Centrifuge 5424, USA). 0.25 ml NOx plasma was immediately transferred into 0.25 ml of 
methanol, mixed, and additionally centrifuged for 15 minutes at 15,000 RPM (Appendix B5). 
Supernatants of the NOx and lactate were transferred into the pre-labeled empty micro-tubes 
(Appendix B6) and kept in ice (0
◦
C) until every blood sample was collected. Approximately, 3ml 
blood was transferred directly into a 4.5ml test tube and centrifuged for 15 minutes at 1,700 g in 
a JS-7.5 rotor in a Beckman J2-21 centrifuge. After centrifugation, the serum was stored at -80
◦
C 
and later used for determination of blood lactate, glucose, and creatine phosphate (Appendix 
B7.1). 
 
Data Collection and Analysis 
Total work, peak torque, fatigue rate, and recovery rate were used to evaluate effects of 
NO-L on knee exercise performance, and metabolic gases were collected and calculated to 
determine the oxygen cost and work efficiency. Blood lactate and glucose samples were 
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analyzed by using enzymatic methods. Blood NOx samples were sent to The University of Texas 
Health Science, Huston for analysis.  
 
Isokinetic Performance Assessment 
Since the data provides unidirectional total work for extension and flexion, to determine 
total work for each set, extension total work and flexion total work for each set were summed, 
and to get entire total work, every set total work was summed. Single peak torque was measured 
as the highest value of torque developed throughout the range of motion. Peak torque used in this 
study was determined by averaging the three highest peak torque values among the first six 
repetitions of each set. In the same way lowest torque was also averaged among the last six 
repetitions per set. Time to peak torque is a measure of time from the start of the knee muscle 
contraction to the point of highest torque development. This index can be used for functional 
ability to produce torque quickly. Fatigue rate was defined as a rate of decline of peak torque 
during exercise and was calculated by the slope of each set peak torque. Recovery rate was 
defined as a rate of incline of peak torque during recovery contractions and was calculated by the 
slope of each contraction peak torque.  
 
Blood Tissue Analysis 
Collected blood tissues were stored at -80°C until analysis. To attain consistent data, 
standard sample was used and every sample was duplicated. 
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Lactate 
Blood lactate concentration was measured by the method of Hohorst (1963). LDH in the 
reagent cocktail convert Lactate and NAD into pyruvate and NADH. The reaction took place in a 
glycine – hydrazine buffer, which allowed pyruvate to interact with hydrazine and the reaction to 
run to completion of assay. The spectrophotometer (Beckman, DU640 spectrophotometer) was 
set a 340 nm wavelength for detection of NADH. The amount of NADH produced was directly 
related to the amount of lactate. 
Glucose 
Glucose oxidase reagent kit (POINTE SCIENTIFIC, INC) contains glucose oxidase 
>15U/ml, peroxidase (horseradish) 800U/L, 4 aminoantipyrine 0.38mM, phosphate buffer, 
pH7.5 ± 0.1, sodium p-hydroxybenzoate 5mM, non-reactive stabilizers and fillers, sodium azide 
0.1%. The spectrophotometer (Beckman, DU640 spectrophotometer) was set at a wavelength of 
500 nm for detection of quinoneimine dye and concentration of glucose was calculated by linear 
equation using 4 standards. The principle is as follows. 
 Glucose oxidase  
1. D-glucose + H2O+O2  
 
 H2O2+D-Gluconate 
 
 POD  
2. H2O2+4-aminoantipyrine+hydroxybenzonate  Quinoneimine dye+H2O 
 
 
Statistical Analysis 
To determine appropriate sample size and power, G power 3.1.7 was used based on the 
statistics of two prior studies in which positive effects (p < .05) were reported. Number of 
subjects was determined from 10 prior experimental studies, which used short-term dietary 
nitrate supplementation, was also referenced (usually 9-12 subjects) (Appendix B8).  
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Data were analyzed using SPSS for Windows, version 19.0 (SPSS Inc., Chicago, IL). 
Metabolic gases (VO2, VCO2, and RER), mechanical performance (work done and peak torque), 
blood samples (glucose and lactate), and hemodynamic (blood pressure and heart rates) were 
analyzed by using two-way repeated-measures ANOVA (Treatment × Time) or Paired t-test. A 
Levene’s test was used to analyze equality of variance. Significant effects from the repeated 
ANOVA were further explored by using an adjusted Fisher’s LSD test. 
To determine whether there was a difference in resting values according to NO 
supplementation, two-way (2×2) repeated ANOA was used. To check the differences between 
NO-L and PLA along the 3 different conditions (post-resting, exercise, and recovery) two-ways 
(2×3) repeated ANOVA was used. To compare exercise variables including work efficiency, 
two-tailed paired t-test was used. In addition, a two-way (2 × 4) repeated ANOVA was used to 
analyze comparison of sets during exercise. All results were expressed by mean  standard error 
and differences were considered significant at a p < .05. 
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RESULTS 
 
Subjects Characteristics 
Seventeen subjects volunteered, but two were screened out because of low VO2max values 
and one dropped out at the familiarization trial due to a fear of needles. A total of fourteen 
subjects successively completed all trials (Appendix C2). The subjects were non-smokers and 
had no medical history related to cardiovascular disease. BMI was 23.7 ± 0.5, VO2max was 47.7 ± 
1.4 ml·kg
-1
·min
-1
, and mean arterial pressure (MAP) was 90.2 ± 1.5 mmHg when they visited the 
laboratory for screening. Their ventilatory threshold (VT) occurred at 165 ± 9 watts while 
cycling and 62.4 ± 3.5 % of VO2max (Table 2 and Appendix A1). 
 
Knee Exercise Performance 
In this study, the exercise was isokinetic knee contractions using a Biodex dynamometer, 
which were not corrected for gravity effect of limb weight.  
Original unidirectional total work and peak torque values were automatically measured 
by the Biodex dynamometer and CSMI isokinetic software, and stored in a computer. We have 
organized the data into bidirectional sum for each work set and total work. To determine peak 
torque during the exercise trials, we used the average of the three highest torque and the three 
lowest torque values among the first and last six contractions, respectively (Appendix A2 to A5). 
 NO-L produced no significant treatment or treatment-by-time interaction effect on work 
done per set or total work performed (Figure 1 and Table 3). In each work set, there was a 
significant decrease in force production over time. The decline in work done occurred mainly 
between the first and second sets, and the work decline was small over the last contraction set. 
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During four exercise sets and six recovery contractions, peak torque (extensor peak torque: EPT, 
flexor peak torque: FPT) was significantly affected by exercise and recovery time (Table 4 and 
5). While NO-L had no effect on knee flexion throughout the fatiguing and recovery periods 
(Figure 4), NO-L had a significant treatment-by-time interaction (p = .021) on rate of recovery, 
particularly between the second and third contractions (p = .034) (Table 4 and Figure 3). NO-L 
had no significant treatment effect on time to peak torque (NO-L: 0.200 ± 0.007sec vs. PLA: 
0.213 ± 0.006 sec; p = .08) although significance was approached. 
 
Energy Metabolism 
Respiratory gas data were used to determine energy metabolism during resting, knee 
exercise, and recovery (Rebergs et al., 2010). The value of net oxygen consumption was used for 
the calculation of work efficiency (Appendix A6 to A12).  
There were interaction effects (p < .05) of resting VO2 and VCO2 between pre and post 
treatment and these values were higher for NO-L post treatment. The post treatment comparisons 
(2×3 repeated ANOVA) showed respiratory gases significantly increased with exercise, and 
there was a significant interaction effect on VCO2 with the value for PLA higher than NO-L. 
There was no interaction or treatment effect on VO2, but there was a meaningful tendency for 
less oxygen to be used during the NO-L treatment. RER values were significantly lower for NO-
L compared with PLA (NO-L: 1.38 ± 0.02 vs. PLA: 1.42 ± 0.02; p = .03 by paired t-test) (Table 
6 and Figure 2).  
Focusing on exercise set during exercise (2×4 repeated ANOVA), there was an 
interaction effect (p = .01) on VCO2, specifically during the 2
nd
 exercise set (p = .01) with 
significantly lower RER values for NO-L (p = .05) (Table 7 and Figure 5 and 6). Oxygen 
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consumption increased with time even though work declined with each exercise set, and VCO2 
peaked during the 3
rd
 exercise set and declined during the 4
th
 exercise set. We found negative 
correlations (p < .01) between oxygen consumption and work done during knee extension 
exercise with no difference in slope for PLA compared with NO-L (NO-L: r = -.546 and PLA: r 
= -.560) (Table 8 and Figure 7 and 8). There was a significant treatment effect on total work 
efficiency for NO-L compared to PLA (NO-L: 2578.7 ± 132.2 ft-lb/l/min vs. PLA: 2497.5 ± 
134.6 ft-lb/l/min; p = .05) (Table 10).  
 
Metabolites and Hemodynamic Indicators 
Resting blood lactate and glucose concentrations were not different between treatments 
(p > .05 by 2×2 repeated ANOVA). Based on data from the post treatment comparisons, there 
was a significant time effect (p < .01 by 2×3 repeated ANOVA) but no difference by treatment. 
Blood lactate was steeply increased with exercise and further increased during recovery, while 
blood glucose was increased with exercise and remained elevated during recovery (Table 9, 
Figure 9 and 10, and Appendix A14 and A15). Throughout the trials, there was no significant 
treatment effect on hemodynamic indicators such as blood pressure or heart rates (Table 11 and 
Appendix A16 to A18).  
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DISCUSSION 
 
Through well-designed previous studies (Ignarro et al., 1987; Brown & Cooper 1994; 
Shen et al., 1994 & 2001; Larsen et al., 2011) we now have a better understanding of how NO 
mediates vascular tone and mitochondrial respiration. In addition, a number of studies have 
explored the nonenzymatic NO generating pathway (Weizberg & Lundberg, 1998; Govoni et al., 
2008; Jansson et al., 2008), From these studies, it was found that dietary nitrates can have a 
positive effects on pathophysiological events as well as on performance (Cosby et al., 2003; 
Larsen et al., 2007; Bailey et al., 2009 & 2010; Wilkerson et al., 2012; Kelly et al., 2013; Bentley 
et al., 2014).  
It is still unclear, however, whether NO has a positive effect on intense resistance 
exercise, although there have been recent human studies that suggest this is a possibility. These 
studies report a reduced ATP turnover rate and enhanced muscle contractile efficiency when 
dietary nitrates are provided (Bailey et al., 2009). In addition, Bailey et al. (2010) found that time 
to exhaustion during high-intensity exercise was significantly increased after nitrate 
administration (586 ± 80 s at PLA vs. 734 ± 109 s at NO) and decline in PCr attenuated (17.10 ± 
5.34 mM at PLA 15.10 ± 4.14 mM at NO). For the reason, the present study investigated the 
effects of three days of dietary nitrate (NO-L) supplementation on vigorous resistance knee 
extension/flexion exercise performance and energy metabolism. The experimental protocol 
applied in this study was inspired by previous studies (Bailey et al., 2009 & 2010; Fulford et al., 
2013; Larsen et al., 2011 & 2014), but we further increased the exercise intensity so that energy 
metabolism was primarily provided by the anaerobic energy system. This is supported by the 
finding that there was a significant inverse correlation (p < .01) found for work per exercise set 
 
 
16 
and oxygen uptake (Figure 8.1 and 8.2). That is, the fall in work with advancing exercise sets 
was due to a decline in anaerobic production and not due to a decline in aerobic energy 
production. Therefore, the present study results will address NO-L effects on intense exercise, 
and the action of nitrate supplementation on anaerobic energy metabolism. 
 
Exercise Performance by Highly repeated Isokinetic Concentric Knee Contractions 
Isokinetic technology has in use to evaluate the individual muscle function such as 
strength and power for elite athlete as well the general population since the late 1960s (Hislop & 
Perrine, 1967) and is regarded as an efficient and safe form of assessment because the resistance 
is accommodated to the force expressed throughout the range of motion (Wyatt et al., 1981). 
Isokinetic concentric measurement at high-speed angular velocity (180°/sec) is normally used to 
test muscle power. Youn (1997) suggested that highly repeated isokinetic contractions can be 
used for evaluation of endurance performance, and Kim (2009) confirmed that 30 seconds of 
isokinetic knee contractions is highly correlated with the Wingate fatigue ratio. In addition, 
highly repeated knee exercise (one minutes at high angular speed) has been proposed to test the 
anaerobic energy system (Douris, 1993) appropriately. For the current study, we designed an 
exercise protocol of four sets of twenty-eight knee extension/flexion contractions at 180°/sec 
speed with each set lasting 30 seconds and with 30 seconds rest between sets. Recovery protocol 
was monitored by performing maximal knee extension/flexion contraction every 120 seconds 
over 12 minutes. This allowed the evaluation of (i) peak torque (ii) muscle endurance, and rate of 
recovery.  
The prominent finding was that extensor peak torque recovery speed was meaningfully 
faster for NO-L (p = .09). Treatment by time analysis indicated that the peak torque for the third 
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recovery contraction was had reached 80% of initial peak torque and significantly greater than 
PLA (p = .034). This positive recovery effect is remarkable when considering the first extensor 
peak torque was 1.6% higher for NO-L and more work done during NO-L (11453 ft-lb at PLA vs. 
11512 ft-lb at NO-L). Therefore, it can be said that NO-L treatment had a positive effect on 
extensor power recovery from the exhausting exercise. It is also noteworthy that time to peak 
torque for NO-L was significantly shorter for both extension and flexion during exercise 
(Extensor: 0.213 ± 0.006 sec at PLA vs. 0.200 ± 0.007 sec at NO-L; p = .08 & Flexor: 0.218 ± 
0.008 sec at PLA vs. 0.209 ± 0.008 sec at NO-L; p = .22). Time to peak torque for knee extensor 
at a speed of 180°/sec occurs between 60° and 50°, when the range of motion is 90° (Knapik et 
al., 1983) and time-wise occurs between 0.166 sec to 0.222 sec. Time to peak torque is used to 
evaluate rate of force production and a delayed time to peak torque suggests a reduced 
recruitment of type II fibers (Kannus, 1994). Since NO-L extensor and flexor times to peak 
torque were superior to PLA during all exercise sets (Appendix A5, extensor p = .04 and flexor p 
= 0.11) it is possible that three days of NO-L may improve motor unit recruitment during 
resistance exercise, particularly in fast twitch muscles.  
 
Energy Metabolism 
Another noticeable finding was that there was a significant difference in RER during 
repeated isokinetic exercise (1.42 ± 0.02 at PLA vs. 1.38 ± 0.02 at NO-L; p = .03). In general, 
RER represents the ratio between carbohydrate and fat oxidations during submaximal exercise 
(Ivy et al., 1979), whereas during server exercise when RER exceeds 1.0, it affected by the 
buffering of hydrogen ions (Wasserman, 1987). The imbalance between hydrogen ion generation 
and removal is one of the reasons causing muscle contraction disturbance (Gladden, 2004). The 
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significantly lower RER found for the NO-L treatment seemed to be accomplished by the 
combine effect of a little less oxygen consumption and much less carbon dioxide production 
(Table 6 and 7). These results are interesting considering there was slightly more work and less 
lactate production during NO-L exercise trial compared with PLA (Table 7 & Figure 1 and 9). 
Collectively, it can be surmised that there was lower metabolic rate in the nitrate 
supplementation trial. This result is in line with recent human studies (Engan et al., 2012; Larsen 
et al., 2014), which reported a lower metabolic rate during apnea and resting after nitrate 
supplementation. Two reasonable explanations include a reduced ATP turnover as suggested by 
Bailey et al. (2009 & 2010) and more efficient mitochondria as suggested by Larsen et al (2011). 
Our results, however, do not support a reduced ATP cost of exercise since there was no 
difference in work between treatments for the third (p = .40) or fourth (p = .51) exercise set or 
total work performed (11453.2 ± 379.8 ft-lb at PLA vs. 11511.8 ± 339.4 ft-lb at LO-L; p = .66). 
If NO-L was reducing the ATP turnover, it seems reasonable that work would be greater for NO-
L from the second set to the end or total work would be meaningfully higher for NO-L than PLA. 
However, there was only slightly more work done during NO-L and during the second exercise 
set, there was 29 ft-lb less work for NO-L compared with PLA. Instead, our results suggest a 
more efficient oxidative phosphorylation process. Larsen et al. (2011) claimed that short-term 
nitrate supplementation lowered the expression of proton channel proteins and the saved protons 
increased the ATPase driving force and thus ATP production. Thus, in our study a slightly 
reduced oxygen cost combined with slightly more total work was connected to an enhanced work 
efficiency (p = .05). It is suggested that additional research be conducted to determine if dietary 
nitrate can improve aerobic metabolic efficiency during intense exercise.  
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Blood Pressure  
The best-known role of NO in the mammalian body is the regulation of vascular tone 
(Ignarro et al., 1987). In this regard, dietary inorganic nitrate supplementations have been 
reported to help lower resting blood pressure in healthy adults (Larsen et al., 2006; Webb et al., 
2008), elderly people (Kelly et al., 2013) and aged people with reduced functional 
hemodynamics (Kenjale et al., 2011). This demonstrates the bioactive form of nitrite works on 
smooth muscle relaxation in both normoxic and hypoxic internal body conditions. Considering 
exogenous NO donor is less effective than enzymatic NO production (Xia et al., 1996), however, 
and there are more NOS activators such as acetylcholine and bradykinin (Pearson & Vanhoutte, 
1993; Victor et al., 2009), the effects of dietary nitrate is not small in terms of a therapeutic 
response. The effect of dietary nitrate on vascular tone may also provide a reason why 
vegetarians have a lower risk of the cardiovascular disease (Lundberg & Weitzberg, 2010).  
In the current study, there was no significant treatment difference resting mean arterial 
pressure (MAP) (p = .45). This is not in agreement with previous studies and we speculate 
several possibilities to explain the current result. First, it is unlike a reliable resting blood 
pressure can be made prior to exercise and when undergoing verbal communication (Long et al., 
1982), limbs positioning (Beevers et al., 2001), and possibly anticipating the exercise to come 
(Handler, 2009). Therefore, to get reliable data of the resting blood pressure, repeated 
measurement and averaging is required. Webb et al. (2008) and Kelly et al. (2013) used averaged 
values, two out of three and three out of four time measurements, respectively. In this study, we 
tried to identically match circadian rhythm, room temperature, resting interval, measurement 
position, and inter-rater reliability between trials, but we did do multiple measurements. Second, 
we confirmed that different positioning resulted in blood pressure changes. Based on these pilot 
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results, we decided to measure blood pressure on the Biodex machine while the subjects were 
wearing metabolic equipment such as head set and mouth peace (Appendix B4). On the other 
hand, pre-treatment resting blood pressure measurements were taken while the subjects were 
seated on normal chair with feet on the floor and the arm supported on a table. Subjects wore no 
equipment during the pre-blood pressure measurements. Comparing MAP from those two 
positions, we saw a big change occurred between the two different positions with Biodex 
position increasing MAP significantly (p < 0.01) regardless of treatment. Third, the measurement 
timing could have been the reason for not finding a treatment effect. Unlike preceding NO 
researches in which approximately two and a half hours is the average timing to initiate blood 
pressure measurement (Vanhatalo et al., 2010; Kelly et al., 2013) or to see the significant 
difference (Webb et al., 2008; Kenjale et al., 2011), we checked the resting blood pressure 
around 37 minutes (Appendix C5) after each treatment. Possibly this short interval did not 
provide enough time to see the bioactive nitrite effect on resting MAP. Increased blood nitrite 
acts as a bioactive precursor for NOS-independent nitric oxide generation (Lundberg & Govoni, 
2004) and the nitrite peak level is known to occur around at two and a half hours after acute 
supplementation (Wylie et al., 2013A).  
One concern about the nitrate effect on blood pressure is whether this is an acute or 
chronic effect. Almost all researches have reported positive effect after two and a half hours of 
supplementation regardless of whether the supplement was provided acutely or chronically 
(Webb et al., 2008; Vanhatalo et al., 2010; Kenjale et al., 2011), and there does not appear to be 
any difference in blood pressure response between acute and chronic supplementation (Webb et 
al., 2008). So it seems that boosted blood nitrite results in a positive effect on resting blood 
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pressure and the impact appears to be acute in nature but needs to be confirmed with varied study 
designs.  
  
Conclusion 
Considering the increase number of individuals participating in resistance exercise, and 
the lack of dietary nitrate studies investigating its impact on intense resistance exercise, the 
current study is noteworthy because (i) it investigated the utilization of the anaerobic energy 
system, and (ii) shorten the loading interval between supplementation and exercise to within 
forty minutes. The study results suggested that three days of lozenge dietary nitrate has a positive 
effect on intense resistance exercise performance by enhancing knee extension time to peak 
torque and rate of recovery, and increased work efficiency.  
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REVIEW OF LITERATURE 
 
Nitric Oxide Chemical Properties 
Nitric oxide (NO) is a small gas compound of a single nitrogen and oxygen atom with a 
molecular weight of 30.01 gram per mole. It acts as an important cell-signaling molecule in the 
mammalian body due to several distinctive chemical characteristics. 
NO can pass through the cell membrane without support of specialized transporter 
proteins because of its small size and uncharged polarity (Pearson & Vanhoutte, 1993). This 
property allows NO to mediate cell functions not only where it is generated but also where it is 
adjacent. Because the NO transportation complies with simple diffusion, NO also moves along a 
concentration gradient (Toledo & Augusto, 2012).  
As a free radical, the unstable electric configuration of NO’s outer orbital-layer is the 
main reason NO easily interacts with many other chemical species. Since NO has a high affinity 
for metal elements like iron and copper, NO rapidly reacts with ferrous iron (Fe2+), Cu
+
, free 
iron, and the iron site of iron-sulfur centers and heme-proteins with liberal ligand place (Cooper, 
1999). In this regard, soluble guanylate cyclase, cytochrome oxidase, and hemoglobin, which are 
well known for typical heme-containing enzymes, would be the main target proteins that directly 
react with NO. (Kelm, 1999; Moncada, 2000).  
Based on its short half-life (milliseconds to seconds depending on concentrations of 
scavenging proteins), NO-mediated physiological effects are transient and rapid. Since it also 
cannot be stored in intact form in many cases, it is normally metabolized to oxyanion forms, 
which are regarded as potential NO sources, like nitrite and nitrate, or transformed to its 
derivative forms whose mediation is more likely to induce structural change and prolonged 
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effects, such as nitrogen oxide, peroxynitrite, and nitrosothiol (Hakim et al., 1996; Hord et al., 
2009; Dudzinski et al., 2006; Tengan et al., 2012). 
 
NO Research Area 
NO is mainly produced by NO generation from the family of nitric oxide synthase 
enzymes (NOSs), which are distributed from the brain to the distal limb muscles. It is, therefore, 
not surprising that NO mediates various pathophysiological events throughout the whole body. 
Based on the study results using a plethora of interventions for NO production, the importance of 
NO-mediated biological effects in various systems have been investigated (Hofmann et al., 2006). 
NO plays key roles in neural signaling for learning and memory (Contestabile et al., 2003) 
as well as normal sexual function (Meldrum et al., 2012). It facilitates cell or tissue defense 
mechanisms against infection and inflammation (Nathan & Hibbs, 1991) by regulating the 
immune system. NO mediates glucose metabolism (Bradley et al., 1999) and mitochondrial 
functions (Shen et al., 2001) in the muscular system, and is a powerful vasodilator, and regulates 
vasomotor tone and blood pressure (Moncada & Higgs, 1993; Webb, 2003). 
Since the critical confirmation that the physiological function of NO and endothelium-
derived relaxing factor (EDRF) are actually not different (Ignarro et al., 1987), a number of 
exercise studies have been conducted. 
Considering the importance of optimal supply of energy sources and recovery materials 
to the skeletal muscle during and after exercise (Stamler & Meissner, 2001), NO’s role on 
regulation of vasomotor tone and thus blood flow has become an attractive area of investigation 
in the exercise science field. It is also known that NO influences mitochondrial respiration and 
oxidative phosphorylation efficiency (Clerc et al., 2007; Larsen et al., 2011A) as well as 
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mitochondrial biogenesis (Nisoli & Carruba, 2006). In addition, recent evidences suggest that 
NO affects the ATP turnover rate (Bailey et al., 2010) and contractile function (Hernandez et al., 
2012) of skeletal muscle. Therefore, it seems appropriate to examine its mechanisms of action 
for facilitating physiological events with respect to exercise performance. 
 
Nitric Oxide Mechanism of Action on Vasodilation 
 
Vasodilation is consequence of Vascular Smooth Muscle Relaxation 
Vasodilation results from the relaxation of vascular smooth muscle tissue, which encloses 
blood vessels that are composed of a single layer of endothelial cells. Unlike skeletal muscle, 
smooth muscle contraction depends on the phosphorylation states of myosin light chain (MLC). 
The phosphorylation of MLC in the smooth muscle leads to contract and dephosphorylation 
leads to its relaxation.  
This unique contractile characteristic of relaxation with dephosphorylation of the MLC is 
caused by (i) reduced affinity between the myosin head and myosin-binding site on the actin 
filament, as well as a weak myosin light chain coupled inactivated myosin ATPase, and (ii) the 
lack of troponin and tropomyosin, which means the myosin-binding site is always open and thus 
there is no need for calcium-activated tropomyosin conformational change for starting cross-
bridge cycling. 
Two enzymes, myosin light chain kinase (MLCK) and myosin light chain phosphatase 
(MLCP), regulate MLC phosphorylation status and the catalytic activities are modulated 
primarily by cytosol calcium concentration [Ca
2+
]i. 
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In a different sense, cytosolic [Ca
2+
] plays a key role in smooth muscle contraction and 
relaxation in that it is a critical factor for determining the downstream effect of Ca
2+
-calmodulin 
(CaM, calcium-binding messenger protein) complex. 
 Elevated Ca
2+
-CaM complex directly promotes MLCK activity (Hofmann et al., 2006). 
As a Ca
2+
-CaM dependent enzyme, MLCK phosphorylates 20-kDa myosin light chain on serine 
residues and thereby potentiates myosin ATPase. This then results in muscle contraction, 
whereas MLCP leads to the reverse reaction when the cytosol calcium level falls (Webb, 2003). 
RhoA (ras homolog gene family member, small GTPase protein)/Rho kinase (ras 
associated protein kinase) is another [Ca
2+
] sensitizing pathway that regulates MLC activity. Rho 
kinase phosphorylates myosin-binding site of MLCP and inhibits MLCP activity. This then 
indirectly helps MLCK to maintain phosphorylation of MLC during smooth muscle contraction 
(Webb, 2003). Therefore, without high level of calcium influx, cross bridge cycling remains in 
the inactive state. 
 
NO mediates Vasodilation through cGKI activity 
NO acts as a potent factor of vascular smooth muscle (VSM) relaxation in that NO is able 
to control both Ca
2+
-CaM and RhoA/Rho kinase induced routes by elevating the cyclic GMP 
dependent protein kinase (cGKI) level. This then affects many downstream activities (Hofmann 
et al., 2006; Pearson &Vanhoutte, 1993). 
NO-related vasodilation is initiated with the simple diffusion NO into neighboring 
smooth muscles. When NO diffuse into the cytoplasm of VSM it binds to an iron-containing site 
found on soluble guanylate cyclase (sGC) and activates the enzyme activity. Activated sGC 
facilitates the hydrolysis of guanosine triphosphate (GTP) followed by increasing the level of 
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cyclic guanosine monophosphate (cGMP). Concentrated cGMP, as a second messenger, turns on 
the chain reaction of cGKI, which is a serine/threonine kinase. cGKI, also known as protein 
kinase G (PKG), is expressed in high level in vascular smooth muscle (Geiselhoringer et al., 
2004). 
Elevated cGKI activity lowers [Ca
2+
]i through (i) phosphorylating and activating 
sarcoplasmic/endoplasmic reticulum Ca
2+
-Mg
+
-ATPase (SERCA), which promotes calcium 
reuptake into the sarcoplasmic reticulum (SR) (ii) phosphorylating or indirectly regulating large-
conductance calcium-activated potassium channels (BKca), which elevates calcium efflux to the 
extracellular matrix (iii) and thereby leading to hyperpolarization inside of the cell and inhibiting 
voltage-dependent calcium channel (L-type calcium channel). This prevents calcium influx to the 
cytosol (Hofmann, 2006). Reducing availability of [Ca
2+
]i leads to reduced Ca
2+
-CaM complex 
and thus restores MLCK into its inactivated dephosphorylated state.  
Moreover, activated cGKI directly activates MLCP activity through the interaction with 
MYPT1, myosin phosphatase target subunit 1 or myosin-binding subunit of MLCP and thus 
dephosphorylates MLC. It also deactivates phospholipase C activity and inositol triphosphate 
(IP3) synthesis, which act as an intermediate signaling of SR calcium release. It may reduce 
RhoA/Rho kinase action by decreasing GTP availability for RhoGEF (Webb, 2003; Moncada & 
Higgs, 1993; Cohen et al., 1998). 
 
NO Action Mechanism on Mitochondrial Functions 
As a terminal enzyme of electron transport chain (ETC), cytochrome c oxidase, 
contributes to electron removing and partly to the electrochemical gradient between the 
intermembrane space and matrix. O2 transiently binds to the Fe
2+
at ferrous-copper (Fe
2+
-CU
+
) 
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binuclear site of cytochrome c oxidase, which takes a total four electrons transferred from the 
series of respiratory enzymes releasing water and heat (Moncada, 2000; Brown, 2001). 
Normal activity of cytochrome oxidase for mitochondrial respiration accounts for ~90% 
of systemic oxygen consumption of mammalian metabolism (Babcock & Wikstrom, 1992). 
Since the O2 amount consumed by the mitochondrial respiration is closely related to the 
production rate of cell-usable energy, ATP, it seems reasonable that oxygen consumed at resting 
or during at least submaximal exercise should be matched with the energy produced. For some 
reasons, however, oxygen utilization through the respiratory enzymes is not precisely coupled 
with oxidative phosphorylation.  
In this case, NO mediations on mitochondrial functions may provide the clue or explain 
the mismatching (Brand et al., 1999). Through the results of the studies using isolated cell and 
mitochondria of astrocytes, hepatocytes, and myocytes in vitro (Cleeter et al., 1994) or animals 
in vivo (Shen et al., 1994), we now know that NO interaction with various mitochondrial sub-
particles cause the mitochondria to function more precisely. 
 
NO Reversibly inhibits Mitochondrial Respiratory Function 
The best-known NO intervention on mitochondrial metabolism is that NO reversibly 
inhibits the cytochrome c oxidase activity by competing with the oxygen molecule on the Fe
2+
- 
CU
+
 binuclear center and thus leads mitochondria to use less oxygen (Boveris et al., 1999). 
Physiological nitric oxide level (0.1nM-100nM) (Bellamy et al., 2002) may inhibit this key 
respiratory enzyme in a non-directional manner resulting in [NO]-dependence (Cleeter et al., 
1994; Brown and Cooper, 1994) and [O2]-dependence inhibition (Poderoso et al., 1996; Brown, 
1999). 
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Reversible NO inhibition is influenced by the redox state of this enzyme. Unlike O2, NO 
is able to bind both oxidized and reduced forms of cytochrome oxidase (Taylor & Moncada, 
2010). In a high [O2] surrounding environment (oxidized form of cytochrome oxidase, Fe
3+
- 
CU
2+
), NO binds to Cu
2+
 without competing with O2 and is instead metabolized to nitrite (NO2
-
) 
maintaining normal function of respiratory enzymes, but under low [O2] tension (reduced form 
of cytochrome oxidase, Fe
2+
- CU
+
), NO binds to ferrous (Fe
2+
) iron competing with O2, 
decreasing oxygen consumption, and increasing reactive oxygen species (ROS), and thus 
producing a toxicity sequence of events (Cooper & Brown 2008).  
It should be mentioned that the duration and degree of NO effects on mitochondrial 
subcomponents is tightly depends on the oxygen concentration (Takehara et al., 1995; Koivisto 
et al., 1997). Effective respiratory half inhibition of [NO]/[O2] ratio was achieved at [60nM] 
/[30µM] and at [270nM]/[145µM] (Brown & Cooper, 1994). Considering the normal oxygen 
concentration is in the range of 20-50µM for cytosol and 1-5µM for mitochondria (Takehara et 
al., 1995), the basal NO level (0.1nM-100nM) may already have crucial effects on mitochondrial 
respiratory function. However, in a normoxic situation reversible inhibition may not cause 
significant reduction of respiratory function because the superfluity of cytochrome oxidase also 
provides oxygen with buffer zone up to a critical point of [NO]/[O2] (Palacios-Callnder et al., 
2007). A significant question is does the reversible inhibition reduce ATP production?  
 
NO Irreversibly mediates Mitochondrial Respiratory Function 
High concentrations of [NO] or [NO]/[O2] ratio tend to retain the reactions with 
superoxide (O2
-
), the iron-sulphur (Fe-S) of complex reductases, and reduced cytochrome 
oxidase. As a result, by-products such as peroxinitrite (ONOO
-
) and S-nitrosothiols (RSNO) are 
 
 
29 
produced. These derivative forms, which are regarded as more stable and also cell damageable 
(Hibbs et al., 1988; Brown, 1997), allow NO to indirectly inhibit the respiratory enzymes 
(Poderoso et al., 1996) in an irreversible manner.  
Activated macrophages or cells, which are part of the inflammation process, provoke 
iNOS enzyme activity by using stimulators like cytokine or endotoxin (Moncada & Higgs, 1993). 
NO released from iNOS activity is accumulated over the basal level and sustained until the 
stimulations are removed.  
At a diffusion limited rate, NO rapidly interacts with superoxide and produces 
peroxynitrite (Heales et al., 1994). Via an oxidizing reaction, peroxynitrite can inhibit 
mitochondrial respiration in an irreversible manner and also damage mitochondrial complexes I 
and II, the ATP synthase, the mitochondrial membrane, and superoxide dismutase (Brown, 1999; 
Cassina & Radi, 1996; Lizasoain et al., 1996; Brookes et al., 1998). In addition, peroxynitrite or 
high levels of NO (>1µM) may irreversibly inhibit cytochrome oxidase and thereby raise its Km 
for oxygen (Sharpe et al., 1998). 
NO interaction with thiols or protein cysteine residues indirectly occurs (Patel et al., 1999; 
Gaston, 1999) and may cause damage on iron-sulfur clusters and released iron from the center 
(Tengan et al., 2012). Nitrosylation of essential thiols in complex I (Clementi et al., 1998) 
inhibits the intact function of the enzyme and this inhibition may depend on glutathione levels. 
Inhibition of complex I is associated with decreased activity of complexes II, III, IV (Bolanos et 
al., 1996). Furthermore, inhibition of complex III excessively increases O2
-
 and thus hydrogen 
peroxide (H2O2), which is also involved in oxidative damage (Moncada, 2000). 
Impaired activity of mitochondrial intermediate enzymes can cause poor energy 
metabolism due to limited electron transferring coupled with less proton efflux and thus reduced 
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ATP production. This then may have significant implication on physical activity issues that 
would evoke anaerobic metabolism. In fact, Brookes et al. (1999) confirmed the hypothesis that 
NO inhibition of mitochondrial respiration will reduce ATP generation by using an isolated brain 
mitochondrial preparation. After adding 4µM NO, ATP production was immediately diminished 
and then recovered up to 70% of control. This result suggested that pathologically induced high 
levels of NO inhibits the mitochondrial function of ATP production and causes irreversible 
damage to inner membrane enzymes.  
 
NO modulates Proton Leak Channels and thus regulate P/O Ratio 
Oxidative phosphorylation efficiency is typically represented by the P/O ratio (Larsen et 
al., 2011). The P/O ratio can be calculated by the rate of ATP produced per oxygen consumed 
during rapid respiration; state 3, in which unlimited oxidizable substrates and ADP allow ATP 
synthase to produce ATP. In this process, proton influx into the matrix provides the driving force 
of the F0/F1 turbine (Noji et al., 1997). During slower rates of oxygen consumption such as state 
4, after ADP depletion or after adding an ATP synthase blocker like oligomycin (Rolfe et al., 
1999) allows the testing of proton leak kinetics. Proton leaks, which include uncoupling proteins 
(UCPs) and adenine nucleotide translocase (ANT) across the inner membrane may account for 
up to 20% of estimated in vivo standard metabolic rate (Rolfe et al., 1999). Divakaruni & Brand 
(2011) suggest that “futile” proton cycling may prevent the host from oxidative damage 
connected to aging or degenerative disorders although state 4-respiration is not necessary for 
ATP production. Considering skeletal muscle metabolism, it seems partly right because 
oxidative phosphorylation is precisely coupled with the energy requirement (Atkinson & Walton, 
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1967; Larsen et al., 2011). Technically, to improve the P/O ratio, it is better to (i) provide 
NADH-linked substrates, and (ii) reduce proton leaks (Clerc et al., 2007). 
Extra NO may have a significant effect on proton leaks via a short-term manner and thus 
affect P/O ratio. In a human study, Larsen et al. (2011) confirmed that there was a significant 
down-regulated expression of ANT (P = .01), which is profound in skeletal muscle, and UCP3 (P 
= .17) after 3 days of sodium nitrate supplementation. As a result, there was significantly less 
state 4 respiration, and improved P/O ratio with the treatment group showing a reduced proton 
leakage and thus improving the driving force at ATP synthase. Coincidently, there was less (P 
= .02) whole body oxygen consumption at 50% VO2max during submaximal cycling 
demonstrating an increase in oxidative phosphorylation efficiency. There was speculation that 
the cell sensed mild hypoxic conditions caused by nitrite, and thus NO exposure over a 
prolonged period of time may elicit signaling pathways to down-regulate ANT. However, 
exactly how short-term nitrate supplementation affects the expression on mitochondrial 
uncoupling proteins remained to be further investigated.  
Shen et al, (1994) were the first to investigate the importance of basal NO on 
mitochondrial metabolism. Their research was the first in vivo study to test whether basal NO 
levels modulate whole body oxygen consumption and tissue oxygen extraction. At resting energy 
requirement, conscious dogs were administrated NLA (L-arginine competitor), which caused an 
increase in tissue oxygen extraction (p < .01) and oxygen consumption (p < .05) compared to 
control levels despite worse hemodynamic indications. This result may indicate the crucial role 
of basal NO in regulating hemodynamics and tissue metabolism; indicate that the down-
regulated expression of proton leak channels is not only mechanism by which mitochondrial 
efficiency in improved. Interestingly, it was found body temperature of the dogs was increased 
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after NO inhibition and indicates that NO’s regulation of oxygen consumption is related to 
thermodynamics. The result also showed indirectly that there was an improved P/O ratio because 
the same resting position and identical experimental conditions were provided for both 
treatments. In another study using isolated guinea pig hearts, Shen et al, (2001) directly 
demonstrated that basal NO improved the P/O ratio by showing reduced oxygen consumption, 
but not ATP production.  
Therefore, it can be said that physiological levels of NO already has a significant role in 
regulating both the mitochondrial respiratory chain and proton dissipation channels. May be that 
basal NO might already inhibit electron transferring and proton pumping since state 4 respiration 
disproportionately increases when the proton gradient raise (Nobes et al., 1990). Collectively, the 
mechanism for how NO improves the P/O ratio seems more related to inhibition of the proton 
leakage. This would (i) increase potential energy to driving ATP production, and (ii) better 
regulate heat production. 
 
Nitric Oxide Generation Passageways 
Under physiological conditions, basal NO supply is mainly accomplished by NO 
production from nitric oxide synthase (NOS), which is placed at specific cellular and tissue 
locations (Alderton et al., 2001). In eukaryotic cells, typically, NOS has three well-known 
isoforms: nNOS (neuronal NOS or type I NOS), eNOS (endothelial NOS or type III NOS), and 
iNOS (inducible NOS or type II NOS) (Stuehr et al., 1999). nNOS and eNOS are responsible for 
constitutive NO generation in the physiological condition and their activities are calcium 
dependent, whereas iNOS is responsible of inducible NO production in under pathological 
conditions and its activity is calcium independent (Lin et al., 2004). 
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Structurally, NOS contains two, an oxygenase and reductase domain. The oxygenase 
domain consists of the binding sites for L-arginine, heme (Fe), and tetrahydrobiopterin (BH4), 
whereas the reductase domain contains the binding sites for flavin mononucleotide (FMN), 
flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide phosphate (NADPH), and 
calmodulin (Alderton et al., 2001). The overall reaction is the movement of electrons from the 
reductase to the oxidase domain. NADPH acts as the initial electron donor, FAD and FMN as 
intermediate electron acceptors, heme and BH4 as intermediate electron acceptors in the oxidase 
domain. Arginine and O2 together are the final electron acceptors. Activation of calcium-
calmoduin facilitates this reaction of nNOS and eNOS, but is not required for iNOS activity 
(Alderton et al., 2001). As a result, L-arginine and O2 are transformed to L-citrullin and NO 
(Bescos et al., 2012).  
It is also well known that NO generation can takes place via a nonenzymatic route in 
which NO production results from chemical reduction of nitrite. Instead of using NOS enzyme, 
this route depends on nitrate or nitrite reductase activity (Weitzberg & Lundberg, 1998). In this 
case, inorganic nitrate, which is rich in green leafy vegetables and beetroot, can serve as 
precursors for nonenzymatic NO production (Hord et al., 2009).  
In the initial step, nitrate ingested into the intestines is taken up in the circulatory system 
and delivered to the salivary glands of the mouth where nitrate is converted to nitrite by 
commensal bacteria (Jansson et al., 2008). The nitrite is reduced to NO through different 
pathways including deoxy-hemoglobin and myoglobin (Lundberg et al., 2008). Nitrite reduction 
to nitric oxide is preferred under hypoxic conditions (Jensen, 2009) due to increased reaction 
availability of the well-known nitrite reductases such as deoxy-hemoglobin, deoxy-myoglobin, 
xanthine oxidoreductase, and protons (Lundbergy et al., 2008). Indeed, in the study of isolated 
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perfused rat heart with ischemia-reperfusion injury (Zweier et al., 1995), there was a 10-fold 
increase in NO production, but it was only partially inhibited by L-NAME infusion showing that 
the NO production route was nonenzymatic. The fact that an internal environment of low pH and 
low [O2] caused by ischemia or hypoxia is optimal for nitrite to be converted to nitric oxide 
(Lundberg, 2008) indicated several potential applications for the NOS independent pathway 
under pathophysiological conditions.  
Compared to rodents, humans have very lower nitrate reductase activity (Jansson et al., 
2008). Nitrate concentration was found to be10-20 fold higher in saliva than blood suggesting 
that oral bacteria is the main way nitrate is converted to nitrite (Lundberg et al., 2004). 
Exogenous nitrate supplementation or diet can be converted to bioactive form of nitrite released 
with limit endogenous nitrate reductase activity.  
 
Nitrate Supplementation Improves Exercise Performance  
Vanhatalo et al. (2010) examined the acute and chronic effects of dietary nitrate 
supplementation on moderate intensity constant cycle exercise and found a lower oxygen cost at 
the same exercise intensity. Bescos et al. (2011) tested a single dose of inorganic nitrate 
supplementation and found that nitrate supplementation significantly reduced VO2max (p = .01) 
and VO2 at a standardized power output (p = .03). Cermak et al. (2012) found that 6days of 
dietary nitrate supplementation in the form of beetroot juice (~0.5 L/day) reduced VO2 during 
sub-maximal exercise and increased tolerance to high-intensity work rates. This suggested that 
nitrate can be a potent ergogenic aid. They also suggested that the mechanism responsible for a 
lower oxygen uptake during exercise is likely related to the role of nitrite and nitric oxide as 
regulators of cellular oxygen utilization. Kelly et al. (2013) investigated the effects of short-term 
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dietary nitrate supplementation and found enhanced VO2 kinetics in the supplement group. 
Larsen et al. (2011) explained that reduced oxygen cost and enhanced metabolism efficiency 
results from an enhanced P/O ratio. This was in part due to a reduced expression ANT, which 
reduced proton leakage. Lansley et al. (2011A) found that acute dietary nitrate supplementation 
improved 4km and 16km cycling time trial performance in competitive cyclists by 2.8% and 
2.7%, respectively. The improved time trial performance after ingestion of nitrate-rich beetroot 
juice was subsequent to a significantly greater power output for the same oxygen consumption. 
Similar effects were shown in different type of exercise. Fulford et al. (2013) investigated the 
effects of dietary nitrate supplementation on resistance exercise performance and found that a 
significant reduction in PCr cost per unit force output in the NO treatment group (Table 1). 
 
Summary 
From vasodilation to mitochondrial function NO mediates many cell-signaling pathways. 
Its mechanism of action is normally accomplished by redox or nitrosative reactions (Andrade et 
all, 1998). NO mediates vasodilation by increasing cGMP dependent protein kinase activity. This 
reduces [Ca2+] and RhoA/Rho kinase activity and thus results in the dephosphorylation of MLC. 
NO also mediates mitochondrial function related to energy metabolism. NO inhibits respiratory 
enzyme proteins and reduces its oxygen utilization both in a reversible and irreversible manner. 
NO also regulates proton leakage by reducing the expression of ANT or UCPs, and this 
contributes to enhanced energy efficiency. Two NO production pathways exists. Nitric oxide 
synthase is the main route generating NO and plays a key role in mammalian tissue under normal 
conditions. eNOS and nNOS are responsible for constitutive NO production, whereas iNOS is in 
charge of inducible NO production among the three isoenzymes. The discovery of a 
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nonenzymatic NO production pathway provided a novel way to generate NO for therapeutic or 
athletic endeavors, but the lack of a reductase, nitrate converting enzyme in manuals can limit 
use of this pathway if one does not have the proper commensal bacteria to reduce nitrate to 
nitrite. However, in recent years many exercise studies have been conducted to the effects of 
nitrate supplementation and found it to have a positive effect on performance.   
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Tables 
 
TABLE 1. Nitrate Supplementation Effects on Exercise Performance 
Author 
(Years) 
Subjects 
 
Supplementation and exercise  
 
Significant results 
 
Larsen FJ 
(2007) 
. 9 males 
. 28±6 years  
. Well-trained cyclists  
. 3days, 0.1 mmol/kg/day of sodium nitrate at 1h before 
the test  
. Incremental cycling test (~35min) 
. ↑plasma nitrite 
. ↓VO2 during sub-maximal exercise 
 
Bailey SJ 
(2009) 
. 9 males 
. 26±6 years 
. Recreationally active 
. 6 days, ~11mmol nitrate 00ml beverage  
. 20w to moderate – 20 min interval – high intensity 
cycle exercise  
. ↑plasma nitrite, ↓systolic blood pressure  
. ↓VO2 cost at moderate 
. ↓VO2 slow component amplitude at high exercise, 
↑time to task failure 
Bescós R 
(2011) 
. 11 males 
. 34.3±4.8 years 
. Cyclists 
. Acute, 10mg/kg body wt. at 3h before the test 
. Incremental cycling  
. ↑plasma nitrate and nitrite 
. ↓VO2 peak 
. ↓VO2: power output 
Lansley KE 
(2011) 
. 9 males 
. 28±4 years 
. Club level cyclists  
. Acute, 6.2mmol of nitrate in 500ml beetroot juice 2.5 
h prior to exercise test 
. 4km and 16km cycling time trials  
. ↑plasma nitrite 
. ↑time trial performance  
 
Larsen FJ 
(2011) 
. 11 males 3 females 
. 25±1 years 
. Healthy nonsmoking 
. 3 days, 0.1mmol/kg/day NaNO3 at 1.5h before the test 
. Sub-maximal cycling (100, 120, or 150 w) until steady 
state 
. ↑plasma nitrate and nitrite 
. ↑P/O ratio and maximal ATP production 
. ↓leak respiration 
Vanhatalo A 
(2011) 
. 7 males 2 females  
. 28±7 years 
. Recreationally trained 
. 1day, 750ml beetroot juice (9.3mmol nitrate) at 24h, 
12h, and 2.5h prior to exercise test 
. Knee extension (~8min) 
. ↑plasma nitrite 
. ↓PCr recovery time  
. ↑task failure time 
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TABLE 1. Nitrate Supplementation Effects on Exercise Performance 
Cermak NM 
(2012) 
. 12 males 
. 31±3 years 
. Cyclists 
. 6 days, ~8 mmol/d nitrate as 140 ml beetroot juice at 
2.5 h before the test 
. 60min sub-maximal cycling and 10km time trial  
. ↑plasma nitrate  
. ↑time trial performance  
. ↓ sub-maximal oxygen cost  
 
Masschlein E 
(2012) 
. 15 males 
. 21.1±1.0 years 
. Healthy active non-
smokers 
. 6 days, 500ml beetroot juice (0.07mmol nitrate/kg) 
. 20 min 45% VO2 peak and incremental cycling  
. ↑plasma nitrate and nitrite 
. ↓oxygen cost at rest and 45% exercise  
. ↑arterial O2 saturation  
 
Wilkerson DP 
(2012) 
. 8 males 
. 31±11 years 
. Club level cyclists 
. Acute, 6.2mmol nitrate beetroot juice 
. 50 mile time trial 
. ↑plasma nitrite 
. ↑correlation b/w nitrite and reduction time trial 
completion time 
Fulford J 
(2013) 
. 8 males 
. 24±4 years 
. Recreationally trained 
. 15 days, 10.2mmol nitrate as 250×2 beetroot juice at 
2.5 h before the test 
. Maximal voluntary isometric knee muscle contractions 
(~10 min) 
. ↑plasma nitrate  
. ↓PCr cost 
Pinna M 
(2014) 
.14 males 
. 34.7±7.5 years 
. Moderately trained 
. Swimmers 
. 6 days, beetroot juice containing 5.5 mmol nitrate 
. Incremental swimming test 
. ↑workload at anaerobic threshold 
. ↓aerobic energy cost 
Molecular Weight; NO: 30.01g/mol  // NO2
- 
: 46.0055g/mol // NO3
-
 : 62.0049g/mol // NaNO2: 68.9953g/mol // NaNO3 : 84.9947g/mol 
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TABLE 3.Total Work (ft-lb), (Mean ± Standard Error) 
Treatment 
 
W 
1
st
 set 
W 
2
nd
 set 
W 
3
rd
 set 
W 
4
th
 set 
W 
Total 
NO-L 
 
4027.50 
±129.29 
2800.50 
±100.55 
2404.50 
±88.62 
2279.29 
±93.67 
11511.79 
±339.38 
PLA 
 
4007.43 
±116.98 
2829.36 
±124.07 
2363.14 
±99.95 
2253.29 
±92.15 
11453.21 
±379.84 
Data represent work of the dominant leg. Each exercise set consisted of 28 repetitions of extensor and flexor work, and total work was the 
sum of all 4 sets. 
 
  
TABLE 2. Subject Characteristics (N=14, Mean ± Standard Error) 
Age 
(yr) 
Height 
(m) 
Weight 
(kg) 
BMI 
 
VO2max 
(l/min) 
VO2max 
(ml/kg/min) 
HRmax 
(bpm) 
MAP  
(mmHg) 
VT 
 (l/min) 
VT 
(watt) 
22.71 
±0.67 
1.75 
±0.02 
72.93 
±2.18 
23.71 
±0.52 
3.45 
±0.10 
47.67 
±1.44 
188.21 
±3.11 
90.17 
±1.42 
2.15 
±0.01 
165.36 
±8.70 
Subjects were non-smokers and had no history of cardiovascular disease. They regularly performed cardio or resistance type workouts 
two to three times a week. VO2max values averaged over 20 seconds. In order to determine ventilatory threshold (VT), VCO2vs VO2 
method was used.  
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TABLE 4. Extension Peak Torque (ft-lb), (Mean ± Standard Error) 
 
Exercise (1~4) Recovery (5~10)
 ‡
 
Treatment 
 
EPT 
1H 
EPT 
2H 
EPT 
3H 
EPT 
4H 
EPT 
1L 
EPT 
2L 
EPT 
3L 
EPT 
4L 
EPT 
5 
EPT 
6 
EPT 
7 
EPT 
8 
EPT 
9 
EPT 
10 
NO-L 108.08 85.56 74.45 70.88 60.12 36.66 31.19 29.92 60.71 74.29 87.07 88.29 91.93 92.79 
 
±3.22 ±2.81 ±3.22 ±3.27 ±1.69 ±1.77 ±1.75 ±1.83 ±5.99 ±6.25 ±5.96 ±4.94 ±4.76 ±4.11 
PLA 106.37 87.66 74.00 72.09 60.01 35.42 31.55 30.31 61.93 77.36 81.79 90.00 89.71 86.29 
 
±3.74 ±3.07 ±3.25 ±3.31 ±2.05 ±1.95 ±2.13 ±1.76 ±6.16 ±5.93 ±5.81 ±4.46 ±4.62 ±4.76 
Each repetition extension peak torque (EPT) was automatically measured by the Biodex machine. EPT High represents average extension 
peak torque of highest three values among first six contractions, and EPT Low among last six contractions. There was a treatment by time 
interaction (p = .02) and between third and forth recovery contraction (NO-L 12.79 ± 3.08 vs. PLA 4.43 ± 2.93; p = .03 by 2×5 repeated 
ANOVA) was significantly different between treatments. 
*
: (p < .05) by paired t-test, 
‡
: (p < .05) by interaction effect, and 
♀
: (p < .05) by 
LSD difference. 
 
TABLE 5. Flexion Peak Torque (ft-lb), (Mean ± Standard Error) 
 
Exercise (1~4) Recovery (5~10) 
Treatment 
 
FPT 
1H 
FPT 
2H 
FPT 
3H 
FPT 
4H 
FPT 
1L 
FPT 
2L 
FPT 
3L 
FPT 
4L 
FPT 
5 
FPT 
6 
FPT 
7 
FPT 
8 
FPT 
9 
FPT 
10 
NO-L 75.69 62.06 56.39 54.35 45.48 31.76 30.87 30.11 54.29 58.50 62.64 63.57 62.29 66.21 
 
±3.86 ±3.57 ±2.97 ±2.88 ±3.11 ±2.30 ±1.89 ±1.28 ±4.10 ±4.17 ±4.96 ±5.28 ±5.49 ±5.38 
PLA 76.09 63.06 54.59 53.84 44.83 32.14 31.39 29.01 55.14 57.57 59.93 63.57 62.29 64.57 
 
±3.49 ±3.62 ±2.62 ±3.12 ±3.31 ±2.33 ±1.61 ±1.47 ±4.10 ±3.93 ±4.53 ±3.91 ±4.09 ±4.23 
Flexion peak torque (FPT) High represents average flexion peak torque of highest three values among first six contractions and FPT Low 
among last six contractions. Overall fatigue rate and recovery rate were significantly changed by time not by treatment. 
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TABLE 6. Metabolic Gases (Mean ± Standard Error) 
 Treatment Pre-resting Post-resting Exercise Recovery 
VO2 
(L/min) 
NO-L 0.27±0.01
‡
 0.29±0.01 1.44±0.06 0.55±0.02 
PLA 0.27±0.01 0.27±0.01 1.45±0.06 0.54±0.02 
VCO2 
(L/min) 
NO-L 0.23±0.00
‡
 0.25±0.01 1.99±0.10
‡
 0.68±0.03 
PLA 0.24±0.01 0.24±0.01 2.06±0.09 0.66±0.03 
RER 
(VCO2/VO2) 
NO-L 0.86±0.01 0.87±0.01 1.38±0.02
*
 1.22±0.01 
PLA 0.89±0.01 0.88±0.02 1.42±0.02 1.22±0.02 
To attain stable and reliable metabolic gas data, resting value was averaged by two to four minute values among five-minute values. 
Interaction of treatment by time was found for resting VO2 and VCO2, but there was no significant difference in resting RER. There was a 
significant interaction effect (p = .018) on VCO2after supplementation, and VCO2 value was lower for NO-L during exercise. There was 
also significant NO-L effect on exercise RER (p = .03). 
*
: (p < .05) by paired t-test,
‡
: (p < .05)by interaction effect, and 
♀
: (p < .05) by 
LSD difference 
 
TABLE 7. Work and Metabolic Gases (Mean ± Standard Error) 
 Treatment 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 
Work 
(ft-lb) 
NO-L 
 
4027.50 
±129.29 
2800.50 
±100.55 
2404.50 
±88.62 
2279.29 
±93.67 
PLA 
 
4007.43 
±116.98 
2829.36 
±124.07 
2363.14 
±99.95 
2253.29 
±92.15 
VO2 
(L/min) 
NO-L 0.96±0.03 1.55±0.08 1.60±0.07 1.64±0.08 
PLA 0.96±0.04 1.60±0.06 1.61±0.07 1.64±0.08 
VCO2 
(L/min) 
NO-L 1.23±0.08 2.15±0.13 2.33±0.13 2.26±0.11 
PLA
‡
 1.22±0.07 2.33±0.11
♀♀
 2.39±0.10 2.28±0.11 
RER 
(VCO2/VO2) 
NO-L* 1.28±0.06 1.39±0.03 1.46±0.03 1.37±0.02 
PLA 1.27±0.05 1.46±0.05 1.49±0.03 1.40±0.02 
Carbon dioxide production was found to be significantly higher at 2
nd
 set of PLA and overall during exercise. RER was significantly 
lower during NO-L over the entire exercise. 
*
: (p < .05) by treatment effect only, 
‡
: (p < .05) by interaction effect, and 
♀
: (p < .05) and
♀♀
: 
(p < .01) by LSD difference  
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TABLE 8. Work and VO2 for Each Exercise Set (Mean ± Standard Error) 
 Treatment 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 
Work 
(ft-lb) 
NO-L 
 
4027.50 
±129.29 
2800.50 
±100.55 
2404.50 
±88.62 
2279.29 
±93.67 
PLA 
 
4007.43 
±116.98 
2829.36 
±124.07 
2363.14 
±99.95 
2253.29 
±92.15 
VO2 
(L/min) 
NO-L 
 
0.96 
±0.03 
1.55 
±0.08 
1.60 
±0.07 
1.64 
±0.08 
PLA 
 
0.96 
±0.04 
1.60 
±0.06 
1.61 
±0.07 
1.64 
±0.08 
Work rate was decreased over time and the difference was largest between the first and second sets. There was significant (p = .01) 
negative correlation between work and oxygen consumption for PLA(r = -.560) and NO-L(r = -.546)  
 
 
 
TABLE 9. Blood Lactate and Glucose (Mean ± Standard Error) 
 Treatment Pre-resting Post-resting Exercise Recovery 
Lactate 
(mM) 
NO-L 
 
1.11 
±0.11 
0.85 
±0.06 
5.75 
±0.57 
7.14 
±0.58 
PLA 
 
1.22 
±0.13 
0.89 
±0.05 
5.94 
±0.53 
6.84 
±0.57 
Glucose 
(mM) 
NO-L 
 
4.46 
±0.07 
4.55 
±0.08 
4.82 
±0.10 
4.86 
±0.12 
PLA 
 
4.38 
±0.08 
4.45 
±0.10 
4.73 
±0.10 
4.65 
±0.12 
There was no change of resting blood lactate and glucose from before and after the treatment. Blood lactate steeply increased during 
exercise and during the recovery the concentration continued to increase. Blood glucose increased after exercise, but there was no 
treatment, time, or treatment by time interaction effect found.  
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TABLE 10. Total Work Efficiency (Mean ± Standard Error) 
 
NO-L PLA 
Total Work Efficiency 
(ft-lb/L/min) 
2578.66* 
± 132.24 
2497.47 
± 134.56 
Total work efficiency was calculated based on the sum of work done from first to the fourth set and sum of net oxygen consumption 
during the exercise. The result showed higher total work efficiency for NO-L, but it only approached statistical significance *:(p = .05) by 
one tail paired t-test. 
 
 
 
TABLE 11. Mean Arterial Pressure (MAP, Mean ± Standard Error) 
 Treatment Pre-resting Post-resting Exercise Recovery 
MAP 
(mmHg) 
NO-L 
 
71.86 
±2.26 
78.50 
±3.04 
84.86 
±3.48 
74.07 
±2.19 
PLA 
 
70.79 
±3.05 
76.86 
±3.48 
87.36 
±3.13 
76.36 
±3.33 
ΔMAP 
(mmHg) 
NO-L 
 
 
 6.36 
±2.31 
          -4.43 
         ±2.12 
PLA 
 
 
10.50 
±2.33 
          -0.50 
          ±3.16 
Mean arterial pressure was calculated by the formula: diastolic pressure + 1/3(systolic pressure – diastolic pressure).  
ΔMAPex-postresting = MAPexercise–MAPpost-restng & ΔMAPrec-postresting = MAPrecovery–MAPpost-restng 
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Figures 
 
 
 
 
FIGURE1. Total work (TW) completed during knee extension and flexion exercise sets. There was 
no significant different between treatments. Bars represents means ± standard errors. 
 
 
 
 
                                                            Exercise 
FIGURE 2. Respiratory exchange ratio (RER) during knee extension and flexion exercise sets. RER 
was significantly higher (p = .03) for PLA. Bars represent means ± standard errors.  
 
* 
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FIGURE 3. Extension peak torque during knee extension/flexion exercise and recovery. No 
significant treatment effect or treatment-by-time interaction was found during exercise sets, but 
there was a significant treatment-by-time interaction (p = .02) and between treatments at the 3rd recovery 
contraction (p = .03). Bars represent means ± standard errors. 
 
 
 
 
 
 
FIGURE 4. Flexion peak torque during knee extension/flexion exercise and recovery. NO significant 
treatment effect or treatment-by-time interaction was found. Bars represents means ± standard errors. 
 
 
* 
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FIGURE 5. Carbon dioxide production (VCO2) during each knee extension/flexion exercise set for 
each treatment. There was a significant treatment-by-time interaction (p = .01) and a significant 
difference between treatments for the 2
nd
 contraction set (p = .01). Bars represent mean ± standard errors. 
 
 
 
 
 
FIGURE 6. Respiratory exchange ratio (RER) during ach knee extension/flexion exercise set for 
each treatment. There was significant treatment effect with RER significantly lower for NO-L (p 
= .05). Bars represent mean ± standard errors. 
 
 
* 
* 
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FIGURE 7. Work completed for each set of knee extension/flexion exercise. No significant 
differences were found between treatments. Bars represent mean ± standard errors. 
 
 
 
 
 
 
FIGURE 8. Oxygen consumption (VO2) for each set of knee extension/flexion exercise. Bars represent 
mean ± standard errors. 
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FIGURE 8.1. Correlation between oxygen consumption (VO2) and work (W) during knee 
extension/flexion exercise for the NO-L treatment (r = -.546 and p < .01).  
 
 
 
 
 
FIGURE 8.2. Correlation between oxygen consumption (VO2) and work (W) during knee 
extension/flexion exercise for the PLA treatment (r = -.560 and p < .01). 
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FIGURE 9. Blood lactate during experimental trials. No significant treatment effect or effect of 
treatment-by-time interaction was found. Bars represent mean ± standard errors. 
 
 
 
 
FIGURE10. Blood glucose during experimental trials. No significant treatment effect or effect of 
treatment-by-time interaction was found. Bars represent mean ± standard errors. 
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FIGURE 11. Total Work efficiency comparison during exercise. Bars represent Mean ± Standard error. 
No significant treatment effect was found (p = .05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
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APPENDICES 
 
Appendix A. Raw Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A1. Subject Basic Information 
Subject 
 
Age 
(yr) 
Height 
(m) 
Weight 
(kg) 
BMI 
(kg/m2) 
VO2max 
(L/min) 
VO2max 
(ml/kg/min) 
HRmax 
(bpm) 
MAP 
(mmHg) 
VT 
(L/min) 
VT 
(RER) 
VT 
(%VO2max) 
VT 
(watt) 
BLA 21 1.70 63.4 22.1 3.11 49.10 183 83.3 1.79 1.05 57.49 145 
BLB 26 1.76 77.0 24.9 3.49 45.30 199 86.7 2.27 1.03 65.09 175 
JRB 28 1.81 68.8 21.1 4.20 61.10 200 86.7 2.89 1.03 68.80 220 
BMK 26 1.75 71.3 23.4 3.20 45.10 177 92.3 2.21 1.08 69.07 175 
TLB 23 1.66 65.8 23.9 2.94 45.20 180 84.3 1.82 1.05 61.77 145 
JMY 19 1.73 68.3 22.8 3.28 48.00 201 91.0 2.07 1.05 63.09 160 
CWC 23 1.68 73.0 25.9 3.28 44.90 202 94.7 2.29 1.07 69.88 190 
OKA 22 1.75 74.5 24.3 3.16 42.70 183 87.3 1.61 1.00 50.92 100 
ERC 22 1.70 65.4 22.6 3.19 49.10 189 86.0 1.87 1.04 58.63 145 
SYK 24 1.84 90.0 26.6 3.83 42.50 196 94.3 2.06 1.06 53.81 145 
NLK 21 1.83 67.6 20.1 3.89 57.60 192 95.3 1.88 1.05 48.31 160 
LFA 21 1.72 79.0 26.9 3.62 45.80 160 84.0 2.87 1.02 79.22 220 
BTA 21 1.90 88.1 24.4 3.87 43.90 190 99.3 2.09 1.05 53.95 145 
SMV 21 1.73 68.8 23.0 3.24 47.10 183 97.0 2.44 0.99 75.17 190 
MEAN 22.7 1.75 72.9 23.7 3.5 47.7 188.2 90.2 2.2 1.0 62.4 165.3 
SE 0.7 0.02 2.2 0.5 0.1 1.44 3.1 1.4 0.0 0.0 3.2 8.7 
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A2.Isokinetic Performances: Work (ft-lb, max GET uncorrected data) 
  NO-L 
    
PLA 
    Subject 
 
W 
1
st
 set 
W 
2
nd
 set 
W 
3
rd
 set 
W 
4
th
 set 
TW 
total 
W 
1
st
 set 
W 
2
nd
 set 
W 
3
rd
 set 
W 
4
th
 set 
TW 
total 
BLA 3573 2708 2425 2320 11026 3649 2894 2617 2320 11480 
BLB 3928 2918 2602 2566 12014 4180 2790 2534 2359 11863 
JRB 3593 3026 2828 2908 12355 3654 3014 2999 2780 12447 
BMK 3864 2650 2149 1917 10580 4032 2540 1860 1921 10353 
TLB 4061 2482 1787 1525 9855 4214 2486 1928 1738 10366 
JMY 3703 2104 1818 1976 9601 3754 2232 1921 1891 9798 
CWC 4190 2705 2358 2330 11583 4052 2850 2315 2226 11443 
OKA 3444 2713 2368 2193 10718 3815 2698 2189 1978 10680 
ERC 3520 2502 2244 2009 10275 2978 2118 1894 1865 8855 
SYK 5036 2940 2492 2278 12746 4386 3355 2459 2511 12711 
NLK 4494 3104 2749 2476 12823 4506 3215 2668 2570 12959 
LFA 4143 2785 2545 2535 12008 4160 2880 2713 2542 12295 
BTA 4822 3770 2899 2648 14139 4771 3927 2786 2747 14231 
SMV 4014 2800 2399 2229 11442 3953 2612 2201 2098 10864 
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A3. Isokinetic Performances: Extension Peak Torque (ft-lb) 
  NO-L                           
Subject EPT1H EPT2H EPT3H EPT4H EPT1L EPT2L EPT3L EPT4L EPT5 EPT6 EPT7 EPT8 EPT9 EPT10 
BLA 92.7 77.7 75.0 79.7 55.0 37.3 35.0 30.3 60.0 99.0 90.0 96.0 98.0 94.0 
BLB 97.7 83.0 75.3 70.7 61.3 37.3 30.0 33.0 74.0 77.0 93.0 84.0 91.0 83.0 
JRB 107.0 98.7 91.3 92.7 65.3 49.7 45.0 48.7 112.0 103.0 106.0 104.0 106.0 103.0 
BMK 102.7 72.0 54.0 49.3 58.0 30.7 25.7 20.3 12.0 15.0 36.0 53.0 63.0 74.0 
TLB 123.3 85.7 62.0 59.0 63.0 31.3 25.3 22.3 48.0 53.0 82.0 78.0 85.0 99.0 
JMY 104.0 77.3 64.0 70.3 52.0 25.3 21.7 24.3 65.0 73.0 66.0 86.0 77.0 74.0 
CWC 104.0 90.3 72.7 72.0 62.7 37.3 36.7 33.0 51.0 83.0 104.0 103.0 108.0 111.0 
OKA 114.0 86.0 88.7 78.3 47.0 45.7 39.7 34.0 62.0 70.0 87.0 69.0 89.0 76.0 
ERC 85.3 69.7 69.3 66.3 59.0 29.7 26.0 27.3 62.0 62.0 68.0 73.0 73.0 70.0 
SYK 121.7 88.7 65.7 53.3 71.7 34.0 24.3 29.0 45.0 70.0 93.0 94.0 78.0 97.0 
NLK 103.0 74.0 64.3 61.0 55.7 32.7 31.0 32.0 54.0 69.0 74.0 82.0 89.0 94.0 
LFA 126.7 98.0 92.7 86.0 62.3 39.7 33.0 32.0 87.0 111.0 130.0 128.0 132.0 120.0 
BTA 119.3 103.0 84.0 75.7 66.7 40.3 29.0 26.0 65.0 82.0 104.0 104.0 110.0 108.0 
SMV 111.7 93.7 83.3 78.0 62.0 42.3 34.3 26.7 52.0 73.0 86.0 82.0 88.0 96.0 
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 PLA 
             Subject EPT1H EPT2H EPT3H EPT4H EPT1L EPT2L EPT3L EPT4L EPT5 EPT6 EPT7 EPT8 EPT9 EPT10 
BLA 95.3 81.0 79.0 76.7 65.0 42.7 37.7 31.3 63.0 94.0 90.0 85.0 95.0 88.0 
BLB 108.0 86.0 74.7 72.3 64.7 30.0 35.0 32.7 71.0 96.0 94.0 104.0 93.0 96.0 
JRB 112.0 98.3 95.0 94.7 58.0 45.3 50.0 48.7 114.0 113.0 116.0 112.0 111.0 108.0 
BMK 96.0 70.0 51.3 44.7 51.7 26.0 19.7 21.3 13.0 37.0 51.0 72.0 70.0 78.0 
TLB 133.3 83.3 68.0 67.0 61.7 29.0 24.3 24.0 55.0 54.0 64.0 80.0 74.0 91.0 
JMY 100.3 80.3 68.3 66.0 49.0 25.0 22.3 26.0 52.0 63.0 64.0 70.0 69.0 62.0 
CWC 107.3 92.3 72.0 69.7 67.3 44.3 36.3 34.0 63.0 83.0 63.0 88.0 90.0 69.0 
OKA 115.7 92.0 78.7 72.3 55.0 43.0 26.3 25.7 70.0 74.0 83.0 92.0 96.0 84.0 
ERC 84.7 70.7 66.0 71.3 45.0 31.3 27.0 26.3 76.0 71.0 75.0 75.0 75.0 70.0 
SYK 84.0 90.3 63.0 61.3 67.3 40.3 31.7 30.0 47.0 61.0 67.0 72.0 72.0 62.0 
NLK 103.3 79.0 68.3 65.3 56.0 32.7 26.7 27.3 60.0 73.0 65.0 86.0 91.0 81.0 
LFA 124.7 108.3 98.7 92.0 66.7 31.3 39.0 34.0 88.0 118.0 126.0 127.0 131.0 121.0 
BTA 117.3 105.7 78.0 81.0 69.7 43.0 34.0 31.7 47.0 79.0 98.0 101.0 95.0 108.0 
SMV 107.3 90.0 75.0 75.0 63.0 32.0 31.7 31.3 49.0 67.0 89.0 96.0 94.0 90.0 
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A4. Isokinetic Performances: Flexion Peak Torque (ft-lb) 
  NO-L                           
Subject FPT1H FPT2H FPT3H FPT4H FPT1L FPT2L FPT3L FPT4L FPT5 FPT6 FPT7 FPT8 FPT9 FPT10 
BLA 60.7 50.7 55.0 49.7 37.3 32.0 32.7 29.0 52.0 60.0 65.0 61.0 70.0 67.0 
BLB 69.7 66.7 64.7 62.0 44.3 37.7 39.0 36.3 53.0 50.0 59.0 52.0 62.0 52.0 
JRB 60.3 55.3 53.7 55.3 45.7 26.7 26.0 31.0 61.0 53.0 58.0 57.0 48.0 53.0 
BMK 73.0 60.7 51.3 47.3 41.7 27.0 28.3 32.0 29.0 29.0 33.0 36.0 34.0 48.0 
TLB 76.0 49.7 41.7 38.3 41.0 28.3 22.3 25.3 41.0 46.0 54.0 55.0 53.0 58.0 
JMY 72.7 52.3 43.7 44.0 40.7 23.3 26.3 27.3 54.0 58.0 62.0 61.0 59.0 64.0 
CWC 75.3 55.7 52.0 51.0 43.3 26.0 26.3 27.3 51.0 66.0 72.0 76.0 75.0 75.0 
OKA 68.7 54.7 52.3 46.7 29.3 26.3 28.0 25.3 28.0 40.0 25.0 26.0 18.0 25.0 
ERC 64.0 55.3 52.0 50.3 43.0 27.0 24.0 24.0 57.0 60.0 57.0 61.0 61.0 59.0 
SYK 108.0 85.0 72.0 68.0 52.7 34.7 41.0 33.3 82.0 86.0 92.0 102.0 98.0 104.0 
NLK 89.0 70.7 64.3 67.0 63.3 48.3 42.0 38.7 63.0 73.0 72.0 77.0 78.0 81.0 
LFA 73.0 60.0 56.0 58.3 38.0 25.3 24.0 25.3 61.0 63.0 78.0 78.0 66.0 80.0 
BTA 102.3 95.3 82.7 76.7 75.7 51.3 41.3 37.0 78.0 83.0 90.0 88.0 88.0 95.0 
SMV 67.0 56.7 48.0 46.3 40.7 30.7 31.0 29.7 48.0 52.0 60.0 60.0 62.0 66.0 
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PLA 
             Subject FPT1H FPT2H FPT3H FPT4H FPT1L FPT2L FPT3L FPT4L FPT5 FPT6 FPT7 FPT8 FPT9 FPT10 
BLA 67.7 55.3 49.0 52.3 40.0 36.0 35.3 27.0 53.0 61.0 66.0 58.0 54.0 57.0 
BLB 76.0 64.0 60.7 60.7 45.0 33.3 38.7 34.3 47.0 49.0 53.0 55.0 59.0 59.0 
JRB 61.7 57.0 58.7 51.7 41.7 33.3 36.0 27.0 72.0 64.0 61.0 57.0 63.0 60.0 
BMK 70.7 65.0 46.0 46.3 39.0 25.7 26.3 36.0 28.0 34.0 40.0 45.0 32.0 40.0 
TLB 74.0 55.3 45.7 41.0 45.3 29.7 27.7 26.3 46.0 49.0 52.0 58.0 55.0 61.0 
JMY 74.0 53.0 46.7 42.7 35.7 23.3 23.7 22.7 49.0 53.0 54.0 56.0 58.0 58.0 
CWC 73.7 59.0 47.0 49.0 44.0 26.3 29.7 26.0 57.0 61.0 64.0 68.0 64.0 67.0 
OKA 73.0 56.7 59.3 50.3 33.3 25.7 24.0 25.0 33.0 41.0 27.0 55.0 60.0 52.0 
ERC 62.7 44.3 39.7 39.3 39.0 24.3 23.0 25.3 55.0 48.0 52.0 50.0 48.0 48.0 
SYK 103.3 83.7 68.7 71.0 52.0 41.3 37.7 41.0 82.0 93.0 99.0 97.0 93.0 98.0 
NLK 89.7 76.3 67.0 66.7 66.3 44.3 38.3 32.3 51.0 65.0 65.0 64.0 68.0 82.0 
LFA 74.0 63.7 58.7 58.7 27.7 22.3 31.0 22.3 67.0 56.0 70.0 78.0 70.0 75.0 
BTA 101.0 95.3 69.7 78.0 74.3 51.7 39.3 33.7 77.0 76.0 78.0 88.0 89.0 87.0 
SMV 63.7 54.3 47.3 46.0 44.3 32.7 28.7 27.3 53.0 56.0 58.0 61.0 59.0 60.0 
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A5. Isokinetic Performances: Time to Peak Torque (Second, Average values) 
  NO-L 
       
PLA 
         1
st
 
 
2
nd
 
 
3
rd
 
 
4
th
 
 
1
st
 
 
2
nd
 
 
3
rd
 
 
4
th
 
 Subject EX FL EX FL EX FL EX FL EX FL EX FL EX FL EX FL 
BLA 0.23 0.25 0.23 0.22 0.22 0.2 0.23 0.18 0.23 0.23 0.21 0.18 0.24 0.17 0.23 0.17 
BLB 0.23 0.2 0.24 0.12 0.25 0.13 0.24 0.14 0.24 0.22 0.25 0.17 0.25 0.14 0.25 0.13 
JRB 0.21 0.24 0.23 0.24 0.24 0.23 0.24 0.2 0.2 0.26 0.22 0.24 0.22 0.23 0.2 0.2 
BMK 0.21 0.21 0.2 0.26 0.21 0.27 0.21 0.25 0.23 0.26 0.21 0.28 0.23 0.27 0.22 0.26 
TLB 0.21 0.21 0.19 0.2 0.17 0.15 0.15 0.18 0.19 0.18 0.2 0.2 0.18 0.16 0.16 0.18 
JMY 0.22 0.27 0.22 0.25 0.21 0.26 0.23 0.23 0.23 0.26 0.23 0.26 0.23 0.25 0.24 0.26 
CWC 0.21 0.22 0.21 0.19 0.19 0.14 0.17 0.11 0.22 0.25 0.24 0.21 0.23 0.2 0.23 0.24 
OKA 0.2 0.27 0.18 0.22 0.19 0.22 0.17 0.19 0.18 0.2 0.15 0.2 0.16 0.22 0.16 0.23 
ERC 0.2 0.2 0.21 0.22 0.21 0.2 0.22 0.19 0.21 0.23 0.24 0.23 0.2 0.2 0.18 0.2 
SYK 0.2 0.2 0.14 0.2 0.15 0.16 0.14 0.23 0.2 0.24 0.23 0.25 0.21 0.25 0.22 0.24 
NLK 0.2 0.2 0.14 0.2 0.15 0.16 0.14 0.23 0.2 0.24 0.23 0.25 0.21 0.25 0.22 0.24 
LFA 0.18 0.21 0.2 0.22 0.18 0.21 0.24 0.24 0.24 0.22 0.23 0.21 0.2 0.22 0.23 0.19 
BTA 0.22 0.22 0.2 0.22 0.19 0.23 0.18 0.21 0.21 0.23 0.21 0.24 0.21 0.21 0.2 0.18 
SMV 0.2 0.27 0.21 0.25 0.2 0.22 0.18 0.16 0.21 0.23 0.2 0.23 0.2 0.17 0.17 0.16 
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A6. Metabolic Gases: VO2 (l/min) 
  NO-L 
   
PLA 
   Subject Pre-resting Post-resting Exercise Recovery Pre-resting Post-resting Exercise Recovery 
BLA 0.2457 0.2568 1.4286 0.5058 0.2664 0.2876 1.5603 0.5818 
BLB 0.2757 0.2920 1.1731 0.4376 0.2626 0.2726 1.1274 0.4432 
JRB 0.2886 0.2895 1.2213 0.4736 0.2762 0.2542 1.2537 0.4487 
BMK 0.2894 0.3123 1.6221 0.6223 0.2760 0.2796 1.6769 0.6218 
TLB 0.2549 0.2855 1.4620 0.5621 0.2983 0.2959 1.4696 0.6058 
JMY 0.2686 0.2673 1.1664 0.5017 0.2287 0.2347 1.2264 0.4794 
CWC 0.2498 0.2959 1.4476 0.6029 0.2426 0.2816 1.5595 0.6018 
OKA 0.2430 0.2662 1.0660 0.3975 0.2926 0.2698 1.1504 0.434 
ERC 0.2686 0.2655 1.4418 0.5554 0.2426 0.2094 1.3998 0.4571 
SYK 0.3023 0.3205 1.3972 0.5923 0.2947 0.2742 1.2922 0.5217 
NLK 0.2639 0.2591 1.7477 0.6278 0.2730 0.2915 1.6937 0.593 
LFA 0.2398 0.2653 1.6991 0.607 0.2328 0.2529 1.7694 0.6276 
BTA 0.3235 0.3526 1.8195 0.6936 0.3106 0.3311 1.7836 0.6729 
SMV 0.3014 0.3016 1.4117 0.5515 0.2974 0.2871 1.3488 0.4916 
MEAN 0.2725 0.2879 1.4360 0.5522 0.2710 0.2730 1.4508 0.5415 
SE 0.0068 0.0073 0.0609 0.0217 0.0071 0.0078 0.0606 0.0218 
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A7. Metabolic Gases: VCO2 (l/min) 
  NO-L 
   
PLA 
   Subject Pre-resting Post-resting Exercise Recovery Pre-resting Post-resting Exercise Recovery 
BLA 0.2198 0.2523 1.9589 0.6263 0.2329 0.2506 2.2247 0.7438 
BLB 0.2165 0.2253 1.6520 0.4825 0.2215 0.2197 1.6886 0.5019 
JRB 0.2442 0.2556 1.5944 0.5640 0.2413 0.2136 1.5740 0.4940 
BMK 0.2392 0.2883 2.2399 0.7508 0.2431 0.246 2.3176 0.7556 
TLB 0.2156 0.2507 2.1004 0.7284 0.2687 0.2732 2.2017 0.7805 
JMY 0.2392 0.2391 1.6055 0.6327 0.1983 0.2049 1.7285 0.6039 
CWC 0.2209 0.2412 1.7782 0.7654 0.2131 0.2172 2.0424 0.7877 
OKA 0.2236 0.2354 1.4464 0.4845 0.2848 0.2504 1.5928 0.5102 
ERC 0.2266 0.2279 1.9404 0.6713 0.213 0.2023 1.9962 0.5280 
SYK 0.2559 0.2704 2.1069 0.7246 0.2898 0.2623 2.0702 0.6681 
NLK 0.2344 0.2417 2.7622 0.8163 0.2367 0.2663 2.6037 0.7309 
LFA 0.2334 0.2261 2.3583 0.7388 0.2099 0.2352 2.3657 0.7706 
BTA 0.2701 0.3126 2.5134 0.8684 0.2787 0.2964 2.4940 0.8347 
SMV 0.2326 0.2462 1.8565 0.6451 0.2332 0.2366 1.8767 0.5882 
MEAN 0.2337 0.2509 1.9943 0.6786 0.2404 0.2411 2.0550 0.6636 
SE 0.0041 0.0066 0.1012 0.0312 0.0079 0.0074 0.0886 0.0328 
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A8. Metabolic Gases: RER 
  NO-L 
   
PLA 
   Subject Pre-resting Post-resting Exercise Recovery Pre-resting Post-resting Exercise Recovery 
BLA 0.8944 0.9826 1.3712 1.2382 0.8743 0.8713 1.4259 1.2784 
BLB 0.7851 0.7716 1.4082 1.1026 0.8435 0.8058 1.4978 1.1324 
JRB 0.846 0.8832 1.3055 1.1907 0.8736 0.8402 1.2555 1.1011 
BMK 0.8267 0.9232 1.3809 1.2065 0.8805 0.8797 1.3821 1.2153 
TLB 0.8458 0.8779 1.4367 1.2958 0.9009 0.9234 1.4981 1.2885 
JMY 0.8907 0.8943 1.3765 1.2611 0.8671 0.8732 1.4094 1.2597 
CWC 0.8843 0.8153 1.2284 1.2697 0.8784 0.7711 1.3096 1.3088 
OKA 0.9204 0.8845 1.3569 1.2189 0.9736 0.9278 1.3845 1.1756 
ERC 0.8437 0.8582 1.3458 1.2087 0.8778 0.9662 1.426 1.155 
SYK 0.8465 0.8436 1.5079 1.2234 0.9836 0.9564 1.6021 1.2806 
NLK 0.8883 0.9327 1.5805 1.3003 0.867 0.9137 1.5373 1.2326 
LFA 0.9731 0.8523 1.388 1.2171 0.9016 0.93 1.337 1.2278 
BTA 0.8418 0.8864 1.3596 1.2331 0.897 0.8964 1.3811 1.2165 
SMV 0.7728 0.8166 1.3184 1.1443 0.7848 0.8253 1.3846 1.1697 
MEAN 0.8614 0.8730 1.3832 1.2222 0.8860 0.8843 1.4165 1.2173 
SE 0.0140 0.0143 0.0229 0.0144 0.0131 0.0154 0.0247 0.0169 
 
  
 
 
61 
 
A9. Metabolic Gases: Each Exercise Set VO2 (l/min) 
  NO-L       PLA       
Subject 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 
BLA 0.8419 1.5129 1.6118 1.7480 0.9504 1.6069 1.7677 1.9160 
BLB 0.9349 1.2165 1.2421 1.2989 0.8673 1.2288 1.2402 1.1732 
JRB 0.8933 1.2483 1.3423 1.4013 0.8356 1.3763 1.3964 1.4064 
BMK 0.9203 1.7554 1.8948 1.9178 0.9707 1.9888 1.8424 1.9056 
TLB 1.0872 1.4921 1.5823 1.6863 1.0601 1.6364 1.5540 1.6281 
JMY 0.8280 1.2122 1.3400 1.2853 0.8491 1.4053 1.3564 1.2949 
CWC 0.9250 1.6292 1.6062 1.6299 0.9015 1.7695 1.8431 1.7239 
OKA 0.7386 1.0906 1.1908 1.2440 0.7875 1.2890 1.2883 1.2369 
ERC 0.9546 1.6130 1.5849 1.6147 0.7958 1.6269 1.4898 1.6867 
SYK 1.0874 1.5535 1.4827 1.4651 0.9212 1.4193 1.4220 1.4064 
NLK 1.2500 1.9416 1.9237 1.8754 1.1979 1.9114 1.8312 1.8343 
LFA 1.0054 1.8736 1.8831 2.0341 1.1011 1.9401 2.0271 2.0095 
BTA 1.0150 2.0360 2.1030 2.1240 1.2984 1.6486 2.0576 2.1297 
SMV 0.8952 1.4623 1.6014 1.6877 0.8436 1.5167 1.4838 1.5511 
 
  
 
 
62 
 
 
 
A10. Metabolic Gases: Each Exercise Set VCO2 (l/min) 
 
NO-L       PLA       
Subject 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 
BLA 1.2536 1.9821 2.1954 2.4045 1.3448 2.2589 2.5269 1.2536 
BLB 1.3790 1.8180 1.7385 1.6724 1.2857 1.9916 1.8700 1.3790 
JRB 1.0702 1.6216 1.8276 1.8580 1.0087 1.6642 1.8492 1.0702 
BMK 1.0132 2.3548 2.9184 2.6733 1.1361 2.8055 2.7528 1.0132 
TLB 1.7052 2.0481 2.3568 2.2916 1.7409 2.4423 2.3687 1.7052 
JMY 0.8509 1.6223 2.0607 1.8882 0.8890 1.9985 2.1053 0.8509 
CWC 0.8394 1.9511 2.1920 2.1303 0.8564 2.1917 2.5961 0.8394 
OKA 0.8548 1.5643 1.6646 1.7021 0.9363 1.8903 1.8871 0.8548 
ERC 1.1130 2.1663 2.2835 2.1988 1.0930 2.2255 2.3481 1.1130 
SYK 1.4798 2.4676 2.3618 2.1183 1.2697 2.4699 2.4177 1.4798 
NLK 1.6646 3.1470 3.3739 2.8635 1.6633 3.0760 2.9734 1.6646 
LFA 1.6081 2.5265 2.6073 2.6914 1.3960 2.6426 2.7693 1.6081 
BTA 1.2458 2.8701 2.9932 2.9444 1.3608 2.8648 2.8700 1.2458 
SMV 1.2013 1.9247 2.1147 2.1855 1.1199 2.0355 2.1732 1.2013 
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A11. Metabolic Gases: Each Exercise Set RER 
  NO-L 
   
PLA 
   Subject 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 
BLA 1.489 1.3102 1.3621 1.3756 1.415 1.4058 1.4295 1.4447 
BLB 1.475 1.4944 1.3997 1.2876 1.4823 1.6207 1.5078 1.3699 
JRB 1.198 1.2991 1.3616 1.326 1.2071 1.2092 1.3242 1.2612 
BMK 1.1009 1.3415 1.5403 1.3939 1.1703 1.4107 1.4941 1.3519 
TLB 1.5685 1.3726 1.4894 1.3589 1.6422 1.4925 1.5242 1.3851 
JMY 1.0276 1.3384 1.5378 1.4691 1.0469 1.4221 1.5522 1.4837 
CWC 0.9075 1.1976 1.3647 1.307 0.9499 1.2386 1.4086 1.4649 
OKA 1.1573 1.4343 1.3979 1.3682 1.1889 1.4665 1.4648 1.34 
ERC 1.1659 1.3431 1.4408 1.3618 1.3735 1.3679 1.5762 1.3743 
SYK 1.3608 1.5884 1.5929 1.4458 1.3784 1.7402 1.7002 1.51 
NLK 1.3316 1.6208 1.7539 1.5268 1.3885 1.6093 1.6237 1.4732 
LFA 1.5994 1.3484 1.3846 1.3231 1.2679 1.3621 1.3661 1.3212 
BTA 1.2123 1.4148 1.4255 1.3858 1.0041 1.7739 1.3948 1.3514 
SMV 1.3419 1.3162 1.3205 1.2949 1.3275 1.342 1.4646 1.4043 
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A12. Correlation between Each Exercise Set VO2 (l/min) and WD (ft-lb) 
  NO-L               
 Subject 1
st
VO2 1
st
W 2
nd
VO2 2
nd
W 3
rd
VO2 3
rd
W 4
th
VO2 4
th
W 
BLA 0.8419 3573 1.5129 2708 1.6118 2425 1.7480 2320 
BLB 0.9349 3928 1.2165 2918 1.2421 2602 1.2989 2566 
JRB 0.8933 3593 1.2483 3026 1.3423 2828 1.4013 2908 
BMK 0.9203 3864 1.7554 2650 1.8948 2149 1.9178 1917 
TLB 1.0872 4061 1.4921 2482 1.5823 1787 1.6863 1525 
JMY 0.8280 3703 1.2122 2104 1.3400 1818 1.2853 1976 
CWC 0.9250 4190 1.6292 2705 1.6062 2358 1.6299 2330 
OKA 0.7386 3444 1.0906 2713 1.1908 2368 1.2440 2193 
ERC 0.9546 3520 1.6130 2502 1.5849 2244 1.6147 2009 
SYK 1.0874 5036 1.5535 2940 1.4827 2492 1.4651 2278 
NLK 1.2500 4494 1.9416 3104 1.9237 2749 1.8754 2476 
LFA 1.0054 4143 1.8736 2785 1.8831 2545 2.0341 2535 
BTA 1.0150 4822 2.0360 3770 2.1030 2899 2.1240 2648 
SMV 0.8952 4014 1.4623 2800 1.6014 2399 1.6877 2229 
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  PLA               
 Subject 1
st
 VO2 1
st
W 2
nd
VO2 2
nd
W 3
rd
 VO2 3
rd
W 4
th
VO2 4
th
W 
BLA 0.9504 3649 1.6069 2894 1.7677 2617 1.9160 2320 
BLB 0.8673 4180 1.2288 2790 1.2402 2534 1.1732 2359 
JRB 0.8356 3654 1.3763 3014 1.3964 2999 1.4064 2780 
BMK 0.9707 4032 1.9888 2540 1.8424 1860 1.9056 1921 
TLB 1.0601 4214 1.6364 2486 1.5540 1928 1.6281 1738 
JMY 0.8491 3754 1.4053 2232 1.3564 1921 1.2949 1891 
CWC 0.9015 4052 1.7695 2850 1.8431 2315 1.7239 2226 
OKA 0.7875 3815 1.2890 2698 1.2883 2189 1.2369 1978 
ERC 0.7958 2978 1.6269 2118 1.4898 1894 1.6867 1865 
SYK 0.9212 4386 1.4193 3355 1.4220 2459 1.4064 2511 
NLK 1.1979 4506 1.9114 3215 1.8312 2668 1.8343 2570 
LFA 1.1011 4160 1.9401 2880 2.0271 2713 2.0095 2542 
BTA 1.2984 4771 1.6486 3927 2.0576 2786 2.1297 2747 
SMV 0.8436 3953 1.5167 2612 1.4838 2201 1.5511 2098 
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A13. Work Efficiency (ft-lb/l/min) 
 
NO-L   PLA 
 
 
Subject 
 
Net VO2 
(l/4min) 
TW 
(ft-lb/4min) 
WE 
(ft-lb/l/min) 
Net VO2 
(l/4min) 
TW 
(ft-lb/4min) 
WE 
(ft-lb/l/min) 
BLA 4.6872 11026 2352.36 5.0904 11480 2255.23 
BLB 3.5244 12014 3408.81 3.4192 11863 3469.53 
JRB 3.7272 12355 3314.82 3.998 12447 3113.31 
BMK 5.2392 10580 2019.39 5.5892 10353 1852.32 
TLB 4.706 9855 2094.14 4.6952 10366 2207.79 
JMY 3.596 9601 2669.91 3.9672 9798 2469.75 
CWC 4.6068 11583 2514.33 5.1116 11443 2238.63 
OKA 3.1992 10718 3350.21 3.5224 10680 3032.02 
ERC 4.7048 10275 2183.94 4.7616 8855 1859.67 
SYK 4.3068 12746 2959.51 4.072 12711 3121.56 
NLK 5.954 12823 2153.68 5.6088 12959 2310.48 
LFA 5.7352 12008 2093.74 6.0664 12295 2026.74 
BTA 5.8676 14139 2409.67 5.81 14231 2449.40 
SMV 4.4404 11442 2576.79 4.2468 10864 2558.16 
Net VO2 = Exercise VO2 – Post-resting VO2, TWD =Sum of work done from 1
st
 set to 4
th
 set 
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A14. Blood Lactate (mM) 
 
NO-L 
   
PLA 
   Subject Pre-resting Post-resting Exercise Recovery Pre-resting Post-resting Exercise Recovery 
BLA 0.87 0.92 7.30 6.50 0.82 0.72 7.50 7.98 
BLB 0.85 0.75 4.02 4.78 0.85 0.82 4.96 4.99 
JRB 1.10 0.69 4.21 3.83 1.13 0.69 2.84 3.82 
BMK 0.96 0.95 4.88 9.86 0.87 0.80 4.60 8.19 
TLB 1.03 1.07 9.40 9.99 1.03 1.07 9.40 9.99 
JMY 1.75 1.43 8.59 6.81 2.17 1.05 8.45 8.76 
CWC 1.52 0.89 3.86 7.08 1.36 0.99 6.12 7.72 
OKA 0.68 0.64 3.66 4.46 1.36 0.83 4.18 3.52 
ERC 0.84 0.77 4.71 7.65 0.65 0.77 6.51 5.22 
SYK 1.89 0.93 3.83 6.99 1.50 1.35 7.19 7.96 
NLK 0.82 0.81 9.67 11.76 0.80 0.81 7.76 9.88 
LFA 0.71 0.83 6.23 6.42 1.02 1.00 5.91 5.28 
BTA 1.68 0.66 5.44 7.12 2.21 0.75 4.46 7.24 
SMV 0.88 0.61 4.65 6.73 1.36 0.75 3.32 5.16 
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A15. Blood Glucose (mM) 
 
NO-L 
   
PLA 
   Subject Pre-resting Post-resting Exercise Recovery Pre-resting Post-resting Exercise Recovery 
BLA 4.01 4.17 4.51 4.30 4.58 4.60 4.98 4.51 
BLB 4.31 4.49 4.77 4.76 4.58 4.46 4.74 4.59 
JRB 4.09 4.35 4.53 4.30 3.96 4.05 4.13 4.14 
BMK 4.36 4.62 4.83 5.32 4.51 4.74 4.9 5.02 
TLB 4.73 4.66 5.46 5.56 4.41 4.73 5.72 5.74 
JMY 4.36 4.61 4.5 4.74 4.15 4.29 4.55 4.67 
CWC 4.39 4.51 4.87 5.05 4.29 4.37 4.7 4.89 
OKA 4.42 4.48 4.61 4.66 3.97 4.23 4.32 4.07 
ERC 4.89 5.11 5.43 5.66 4.77 4.77 4.87 4.87 
SYK 4.4 4.18 4.59 4.66 4.54 4.69 4.74 4.65 
NLK 4.45 4.51 4.59 4.88 4.27 4.29 4.5 4.53 
LFA 4.69 4.3 4.69 4.6 3.79 3.47 4.25 4.08 
BTA 4.93 5.20 5.53 5.35 4.80 4.79 4.93 4.79 
SMV 4.37 4.44 4.57 4.25 4.67 4.78 4.83 4.59 
 
  
 
 
69 
 
A16. Blood Pressure (mmHg) 
 
NO-L 
       
PLA        
Subject 
BP 
1S 
BP 
1D 
BP 
2S 
BP 
2D 
BP 
3S 
BP 
3D 
BP 
4S 
BP 
4D 
BP 
1S 
BP 
1D 
BP 
2S 
BP 
2D 
BP 
3S 
BP 
3D 
BP 
4S 
BP 
4D 
BLA 127 70 122 84 156 89 125 73 123 71 137 83 155 90 131 73 
BLB 125 72 111 69 150 78 120 72 128 72 114 78 148 98 128 74 
JRB 108 73 100 76 126 79 100 55 102 71 110 78 130 68 92 61 
BMK 129 78 136 85 172 100 137 82 122 72 130 79 171 89 133 69 
TLB 121 58 126 71 153 69 119 69 114 64 141 74 161 82 143 81 
JMY 104 69 110 84 132 80 114 71 103 69 104 75 121 72 99 69 
CWC 114 71 120 71 167 86 136 98 115 75 127 79 162 78 140 82 
OKA 108 59 107 60 135 91 109 69 115 56 108 73 147 71 122 70 
ERC 115 62 124 82 132 92 130 87 117 73 104 74 128 80 117 74 
SYK 114 71 120 66 123 76 117 77 111 69 114 72 120 77 112 74 
NLK 104 60 102 71 144 86 110 67 115 73 105 75 167 85 126 68 
LFA 99 61 108 67 150 82 116 70 121 65 130 76 163 80 118 74 
BTA 129 78 135 89 157 91 141 83 122 67 112 80 163 86 140 74 
SMV 118 77 116 80 142 88 105 55 114 81 113 73 137 85 102 64 
BP 1: Pre-resting, BP 2: Post-resting, BP 3: Exercise, BP 4: Recovery& S: systolic, D: diastolic 
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A17. Mean Arterial Pressure (mmHg) 
  NO-L 
   
PLA 
   Subject Pre-resting Post-resting Exercise Recovery Pre-resting Post-resting Exercise Recovery 
BLA 71 83 90 73 70 84 89 73 
BLB 72 78 98 74 72 69 78 72 
JRB 71 78 68 61 73 76 79 55 
BMK 72 79 89 69 78 85 100 82 
TLB 64 74 82 81 58 71 69 69 
JMY 69 75 72 69 69 84 80 71 
CWC 75 79 78 82 71 71 86 98 
OKA 56 73 71 70 59 60 91 69 
ERC 73 74 80 74 62 82 92 87 
SYK 69 72 77 74 71 66 76 77 
NLK 73 75 85 68 60 71 86 67 
LFA 65 76 80 74 61 67 82 70 
BTA 85 91 112 96 95 104 113 102 
SMV 91 92 106 72 92 86 102 77 
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A18. Heart Rates (beat per minute) 
 
NO-L 
            Subject HR 1 HR 2 HR 3 HR 4 HR 5 HR 6 HR 7 HR 8 HR 9 HR 10 HR 11 HR 12 HR 13 
BLA 57 65 160 157 168 173 116 101 101 92 95 93 86 
BLB 67 63 168 159 161 166 101 91 85 86 86 83 72 
JRB 79 75 122 126 121 137 106 92 87 84 87 88 83 
BMK 61 59 142 154 164 164 121 98 96 95 94 92 90 
TLB 56 59 150 150 155 158 111 100 99 103 94 87 87 
JMY 85 61 139 147 144 153 116 109 106 101 100 102 85 
CWC 63 62 147 146 156 161 101 82 84 90 88 83 88 
OKA 59 59 138 118 137 128 67 74 71 65 63 69 69 
ERC 57 62 133 122 172 178 121 101 97 97 88 96 92 
SYK 58 58 162 164 170 172 121 100 93 89 87 84 81 
NLK 54 56 162 166 171 175 121 115 102 100 102 104 99 
LFA 51 53 127 126 132 136 84 81 74 72 75 72 70 
BTA 76 77 143 153 156 158 124 109 107 110 105 105 101 
SMV 63 59 154 154 164 170 105 85 87 83 80 84 82 
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PLA 
            Subject HR 1 HR 2 HR 3 HR 4 HR 5 HR 6 HR 7 HR 8 HR 9 HR 10 HR 11 HR 12 HR 13 
BLA 65 65 152 153 170 175 125 115 100 99 96 94 83 
BLB 72 64 169 162 163 163 99 92 89 88 86 86 77 
JRB 73 70 126 124 129 125 98 85 88 81 79 82 74 
BMK 65 65 136 150 150 159 113 100 92 91 88 92 80 
TLB 51 53 158 156 156 161 119 116 108 103 96 94 94 
JMY 69 70 141 148 153 162 121 119 111 107 105 104 98 
CWC 65 67 142 157 165 172 106 122 103 105 90 88 88 
OKA 55 58 128 128 126 118 67 64 68 62 71 67 70 
ERC 50 60 162 159 161 166 97 80 73 70 75 75 89 
SYK 62 69 145 158 158 163 95 95 87 85 82 79 77 
NLK 60 56 164 166 174 176 120 102 97 97 95 98 93 
LFA 52 52 126 127 136 141 85 79 76 71 75 73 70 
BTA 67 74 127 145 149 151 113 104 98 95 92 90 91 
SMV 67 62 143 150 152 162 94 93 78 85 84 79 66 
HR 1: Pre-resting, HR 2: Post-resting, HR 3 to HR 6: Exercise 1
st
 to 4
th
, HR 7 to HR 13: Recovery of 4
th
 to 10
th 
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A19. Estimated Each Exercise Set Power (watts) 
  NO-L 
   
PLA 
   Subject 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 1
st
 set 2
nd
 set 3
rd
 set 4
th
 set 
BLA 302.8 229.5 205.5 196.6 309.3 245.3 221.8 196.6 
BLB 332.9 247.3 220.5 217.5 354.3 236.5 214.8 199.9 
JRB 304.5 256.5 239.7 246.5 309.7 255.4 254.2 235.6 
BMK 327.5 224.6 182.1 162.5 341.7 215.3 157.6 162.8 
TLB 344.2 210.3 151.4 129.2 357.1 210.7 163.4 147.3 
JMY 313.8 178.3 154.1 167.5 318.2 189.2 162.8 160.3 
CWC 355.1 229.2 199.8 197.5 343.4 241.5 196.2 188.7 
OKA 291.9 229.9 200.7 185.9 323.3 228.7 185.5 167.6 
ERC 298.3 212.0 190.2 170.3 252.4 179.5 160.5 158.1 
SYK 426.8 249.2 211.2 193.1 371.7 284.3 208.4 212.8 
NLK 380.9 263.1 233.0 209.8 381.9 272.5 226.1 217.8 
LFA 351.1 236.0 215.7 214.8 352.6 244.1 229.9 215.4 
BTA 408.7 319.5 245.7 224.4 404.3 332.8 236.1 232.8 
SMV 340.2 237.3 203.3 188.9 335.0 221.4 186.5 177.8 
Estimated workload = each set work done × 0.0226 × 2 × 60/32  
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Appendix B. Method Details 
 
 
  
B1. VO2maxTest Protocol for Non-Athlete Active Subject 
 
Stage 
Watts (circle protocol chosen) 
Record Time RPE (6-20) 
HR 
(bpm) Female Male 
Low<80kg High≥80kg 
1(00:00-02:00) 100 100 100 01:50   
2(02:00-03:00) 115 115 120    
3(03:00-04:00) 130 130 140 03:50   
4(04:00-05:00) 145 145 160    
5(05:00-06:00) 160 160 180 05:50   
6(06:00-07:00) 175 175 200    
7(07:00-08:00) 190 190 220 07:50   
8(08:00-09:00) 200 205 240    
9(09:00-10:00) 210 220 260 09:50   
10(10:00-11:00) 220 235 280    
11(11:00-12:00) 230 250 300  11:50   
12(12:00-13:00) 240 265 320 12:50   
13(13:00-14:00) 250 280 340 13:50   
14(14:00-15:00) 260 295 360 14:50   
15(15:00-16:00) 270 310 380 15:50   
Cool down 
Stop Time: 
____:____ 
Max Watts: 
___ 
HRmax (bpm): 
____ 
VO2max 
(ml/kg/min): 
______ 
Min 5: 
HR _____bpm 
Subjects warmed up for 5min with cycling ergometer or on the floor before starting VO2max test. Exact indication was given and urged subjects to 
keep the minimal 60RPM when they pointed out Borg scale “very hard”. 0 workload was given right after they were all-out to cool down properly and 
recovery heart rates was continuously monitored during 5min after the test.  
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B2. Experimental Protocol Time Frame 
Protocol Stage 
Time Before &After 
Treatment  
(Min: sec) 
Interval Time 
Between stages 
(Min: sec) 
Measurements 
In order 
    Subject Check-in - 20:00 5  
Baseline (Pre treatment) - 15:00 10 MC, HR, BP, BD 
Study product intake - 5:00 35  
    Baseline (Post treatment, pre exercise) 30:00 10 MC, HR, BP, BD 
    
Resistance exercise 1
st
 set 40:00 to 40:30 00:30 MC, HR 
Resistance exercise 2
nd
 set 41:00 to 41:30 00:30 MC, HR 
Resistance exercise 3
rd
 set 42:00 to 42:30 00:30 MC, HR 
Resistance exercise 4
th
 set 43:00 to 43:30  02:00 MC, HR, BD, BP  
    
1
st
 one maximal contraction 45:30 02:01 MC, HR 
2
nd
 one maximal contraction 47:31 02:01 MC, HR 
3
rd
 one maximal contraction 49:32 02:01 MC, HR 
4
th
 one maximal contraction 51:33 02:01 MC, HR 
5
th
 one maximal contraction 53:34 02:01 MC, HR 
6
th
 one maximal contraction 55:35 00:01 MC, HR 
    End of last one maximal contraction 57:36  BD, BP, HR 
Blood Draw (BD), Blood Pressure (BP), Heart Rate (HR), Metabolic Cart (MC) 
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B3. Overall Procedure 
 
 Pre-treatment Post-treatment 
 
 
 
 
 
Trial 1 
 
1
st
 
Supplementation  
2 days before 
 
 
2
nd 
Supplementation  
1 day before 
Check-in  Resting 
 
 
3rd 
Supplementation 
on the trial day 
 
30min interval 
b/w resting 
Resting 
 
 Exercise 
 
180◦/sec 
28reps 
× 4sets 
30sec 
interval 
 Recovery 
 
180◦/sec 
1rep 
× 6sets 
120sec 
interval 
 Check-out 
↑ 
BM 
 
FBG 
 
 
↑ 
BD 1 
 
BP 1 
↑ 
5 min 
MG 
 
HR1 
↑ 
5 min 
MG 
 
HR2 
 
↑ 
BD 2 
 
BP 2 
↑ 
4 min 
MG 
 
HR3~6 
↑ 
BD 3 
 
BP 3 
↑ 
13 min 
MG 
 
HR7~12 
↑ 
BD 4 
 
BP 4 
 
HR13 
  
↑ 
1 week apart 
↓ 
 
 
 
 
 
Trial 2 
 
1
st
 
Supplementation  
2 days before 
 
 
2
nd 
Supplementation  
1 day before 
Check-in  Resting 
 
 
3
rd
 
Supplementation 
on the trial day 
 
30min interval 
b/w resting 
Resting 
 
 Exercise 
 
180◦/sec 
28reps 
× 4sets 
30sec 
interval 
 Recovery 
 
180◦/sec 
1rep 
× 6sets 
120sec 
interval 
 Check-out  
↑ 
BM 
 
FBG 
 
 
↑ 
BD 1 
 
BP 1 
↑ 
5 min 
MG 
 
HR1 
↑ 
5 min 
MG 
 
HR2 
↑ 
BD 2 
 
BP 2 
↑ 
4 min 
MG 
 
HR3~6 
↑ 
BD 3 
 
BP 3 
↑ 
13 min 
MG 
 
HR7~12 
↑ 
BD 4 
 
BP 4 
 
HR13 
  
 
BM: body mass, FBG: fasting blood glucose, BD: blood drawing, BP: blood pressure, MG: metabolic gas, HR: heart rate 
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B4. Resting and Exercise Positions 
 
1. Resting position 
 
 
 
2. Exercise position 
 
 
 
 
Isokinetic knee exercise: isokinetic knee exercise was designed to measure repeated peak torques and total work done during 
extensor/flexor muscle contractions at dominant leg only. The Biodex dynamometer system (Biodex, 900-760, USA) was set up to 
support concentric contractions only at 180°/sec of angular velocity. The range of motion for the knee extension/flexion was set up at 
90°. Muscle force and power was determined for each contraction. Subjects performed maximal knee muscle contractions at 180°/sec 
angular speed for 4sets × 28 reps with 30 seconds of rest between sets. Following the isokinetic knee extension/flexion bout, the 
subjects performed one maximal isokinetic contraction every 2 min for 12 minutes.  
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B5. Making Solutions 
How to make solutions for aliquot 
 200ml EDTA (pH 7.4) 
Preparation:  4.8g of ED2SS powder (24mgper ml), distilled water, pH meter, stirring magnet, and beaker  
1.150ml of distilled water + 4.8g of ED2SS into the beaker& stirring 
2. Adjusting pH with NaOH and HCl to the 7.4 
3. Adding distilled water up to 200ml with adjusting pH little 
 50ml Methanol  
: 99.9% methanol (F.W: 32.04) into the 50ml effendorf tube 
 200ml 10% PCA 
Preparation: 70% perchloric acid liquid, distilled water, stirring magnet, and beaker 
1. 150ml of distilled water + 28.57ml of 70 % perchloric acid liquid into the beaker& stirring 
2. Adding distilled water up to 200ml  
How to make solutions and reagents for lactate sample assay 
 Reagent cocktail for each tube 
Preparation: 1ml glycine – hydrazine buffer, 0.83mg of NAD, 5µl of LDH, stirring magnet, and 50ml effendorf tube or beaker 
1. Calculating the #of tubes considering 2~3ml extra 
2. Glycine –hydrazine buffer, NAD, LDH into the effendorf tube or beaker and mixing 
 1000ml glycine – hydrazine buffer (pH9.8) 
Preparation: 0.33M glycine 25.02g, 0.27M hydrazine 23.98ml, distilled water, pH meter, stirring magnet, and beaker 
1. 900ml of distilled water + 22.02g of glycine powder + 23.98ml of 0.27M hydrazine 
2. Adjusting pH with NaOH and HCl to the 9.8 
3. Adding distilled water up to 1000ml with adjusting pH little 
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B6. Tube Labeling 
 
Label was marked on top and side of empty 1.5 ml tube as following method.  
Abbreviation  
NO-L: NO-L supplementation study 
NOx: Plasma nitrate and nitrite sample 
Lac: Whole blood lactate sample 
Glu: Serum glucose sample 
T #: Trial order 
BD #: Blood sampling order 
 
For example, if the subject’s name is Kyoungrae Kim and it is 1sttrail 1 for blood samples, 
 
NO-L NOx 
KRK-T1 
BD1 
→ NO-L NOx 
KRK-T1 
BD2 
→ NO-L NOx 
KRK-T1 
BD3 
→ NO-L NOx 
KRK-T1 
BD4 
 
NO-L Lac 
KRK-T1 
BD1 
 
→ 
 
NO-L Lac 
KRK-T1 
BD2 
 
→ 
 
NO-L Lac 
KRK-T1 
BD3 
 
→ 
 
NO-L Lac 
KRK-T1 
BD4 
 
NO-L Glu 
KRK-T1 
BD1 
→ NO-L Glu 
KRK-T1 
BD2 
→ NO-L Glu 
KRK-T1 
BD3 
→ NO-L Glu 
KRK-T1 
BD4 
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         B7. Blood Handling 
 
12 x 17 
Empty tube
4.5ml
SST tube
EDTA  
50ul
10% PCA
0.8ml
Spin 1700g for 15min
3ml blood2ml blood
Methanol
250ul
Spin 1700g for 15 min
1ml blood 0.4ml blood
250ul plasma
CKNOx
Spin 15000rpm 
for 15 min
Supernatant
Supernatant
5ml blood sample
Supernatant
GluLac
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B7.1. Blood Handling Detail 
 
BD1 
EDTA BD1 & 
PCA BD1 
 
15min 
At 1700 RCF 
SST BD1 
 
45min at RT 
45min at 0◦C 
 
 
 
→ 
250µl of plasma into  
the Met BD1 
 
15min 15000 RPM 
 
 
 
→ 
 
 
Supernatant of Met BD1 into 
the sample tube 
(NOx BD1) 
 
 
 
→ 
Every sample tubes were kept in 
the 0
◦
C ice box until move into 
the -80
◦
C refrigerator  
 
 
Supernatant of PCA into the 
sample tube  
(LacBD1) 
EDTA BD2~4 & 
PCA BD2~4 
 
Kept in the 0
◦
C ice box until s of 
BD4 is finished 
BD2 to BD4 
 
EDTA BD2~4 & 
PCA BD2~4 
 
15min 
At 1700 RCF  
SST BD1~4 
 
15min 
at 1700 RCF 
 
 
 
→ 
250µl of plasma into  
the Met BD2~4 
15min 15000 RPM 
 
 
 
 
→ 
 
 
 
Supernatant of Met BD2~4 into 
the sample tube 
(NOx BD2~4) 
 
 
 
→ 
 
 
Every sample tubes were move 
into the  
-80
◦
C refrigerator immediately 
after every sampling was 
finished  
Supernatant of PCA  
into the sample tube  
(LacBD2~4) 
Supernatant of SST 
Into the sample tube 
(Glu& CK BD2~4) 
  
 
 
82 
B8. Determining Sample Size and Power 
 
 
Method1. G power 3.1.7 
Reference Dependent Variables 
Test Family 
Power P value Effect Size Tailed Minimum 
Sample Size 
Actual Power 
Fulford et al., 2013 PCr cost 
Paired t-test 
.80 .05 .580 One-tailed 20 
.80 
Larsen et al., 2011 PO ratio 
Paired t-test 
.80 .05 1.07 Two-tailed 9 
.802 
 
 
Reference 
Fulford J, Winyard PG, Vanhatalo A, Bailey SJ, Blackwell JR, Jones AM. 
Influence of dietary nitrate supplementation on human skeletal muscle metabolism and force production during 
maximum voluntary contractions. Pflugers Arch. 2013. 465(4): 517-28.  
Larsen FJ, Schiffer TA, Borniquel S, Sahlin K, Ekblom B, Lundberg JO, Weitzberg 
E. Dietary inorganic nitrate improves mitochondrial efficiency in humans. Cell Metab.2011. 13(2): 149-59.  
 
Method2. Normal range of sample size  
Minimum: 7 (Bailey et al., 2010) 
Maximum: 15(Masschleinet al., 2012) 
Averaging: usually 9-12 males participate  
My decision for proper sample size and power of NO-L study was 12 - 14 males.  
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Appendix C. Procedure Details 
 
C1. Randomization 
 
Subject T1 treatment T2 treatment 
BLA PLA NO-L 
BLB PLA NO-L 
JRB PLA NO-L 
BMK NO-L PLA 
TLB PLA NO-L 
JMY PLA NO-L 
CWC NO-L PLA 
OKA PLA NO 
ERC NO-L PLA 
SYK NO-L PLA 
NLK NO-L PLA 
LFA NO-L PLA 
BTA NO-L PLA 
SMV PLA NO-L 
Randomization NO-L=7 vs. PLA=7 NO-L=7 vs. PLA=7 
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C2. Participant Visit Schedules 
 
Mon Tue Wed Thurs Fri Sat 
5/12 
10:20 BMK – V1 
 
5/13 
08:20 TLB – V1 
 
5/14 
 
5/15 
08:00 CWC – V1 
10:30 OKA – V1  
5/16 
08:30 ERC – V1 
 
5/17 
5/19 
 
5/20 
17:30 SYK – V1  
5/21 
 
5/22 
11:00 NLK – V1  
5/23 5/24 
5/26 5/27 
08:00 TLB- FAM 
5/28 
08:00 OKA - FAM  
5/29 
08:00 CWC – FAM 
5/30 
08:00 ERC - FAM  
5/31 
6/2 
 
6/3 
08:00 TLB- T1 
6/4 
08:00 OKA – T1 
6/5 
08:00 CWC – T1 
6/6 
08:00 ERC – T1  
6/7 
6/9 
07:00 SYK – FAM 
15:00 LFA – V1  
6/10 
08:00 TLB- T2 
6/11 
08:00 OKA – T2 
10:30 BLB – FAM 
6/12 
08:00 CWC – T2 
6/13 
08:00 ERC – T2  
10:30 NLK – FAM 
6/14 
 
6/16 
07:00 SYK – T1 
6/17 
13:30 JRB – V1 
 
6/18 
08:00 LFA – FAM 
10:30 BLB – T1 
6/19 6/20 
08:00 BLA – FAM  
10:30 NLK – T1 
6/21 
10:00 BMK – FAM 
6/23 
07:00 SYK – T2 
11:00 JRB – FAM  
6/24 
16:40 JMY – V1  
6/25 
08:00 LFA – T1 
10:30 BLB – T2 
6/26 6/27 
08:00 BLA – T1  
10:30 NLK – T2 
6/28 
12:30 JMY – FAM 
6/30 
11:00 JRB – T1 
14:00 BMK – T1 
7/1 7/2 
08:00 LFA – T2  
7/3 
10:30 JMY – T1  
7/4 7/5 
7/7 
11:00 JRB – T2 
14:00 BMK – T2 
7/8 
9/2 
13:30 BTA –V1 
7/9 7/10 
10:30 JMY – T2 
 
7/11 
08:00 BLA – T2  
9/5 BTA - FAM 
7/12 
9/8 
 
9/9 9/10 9/11 
15:30 SMV – V1 
9/12 
11:30 SMV – FAM 
9/13 
9/15 
 
9/16 9/17 9/18 
 
9/19 
09:00 BTA – T1 
11:30 SMV – T1 
9/20 
9/22 
 
9/23 9/24 9/25 
 
9/26 
09:00 BTA – T2 
11:30 SMV – T2 
9/27 
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C3. Supplies 
 
Supplements 
FAM Trial 1 Trial 2 
. 2 lozenges for 2 days before the trial 1 
. Instruction how to intake the tablet 
. 1 lozenge for the trial 1  
. 2 lozenges for 2 days before the trial 2 
. 1 lozenge for the trail 2 
 
 
Reminder Email and texting (Every day checking)  
: Reminder email 2 days before the Screening 
: Text message 1 day before the Screening 
: Reminder email 3 days before the FAM, T1, and T2 
: Text message 2 days before the FAM, T1, and T2 
 
Blood sampling 
: Catheter, saline pack, Tegaderm
TM
 film, connecter line, luer access split septum, 20G1 needle, gauze sponges, alcohol prep pad, 
diaper, gloves, hand sanitizer, small timer, tourniquet, tapes 
: Blood glucose monitor 
 
Aliquot 
: 50 µ EDTA into the ml tubes, 250 µl Methanol into the ml tube, 800 µl 10% PCA into the ml 
: Everyday sample tubes labeling and double check with Bo 
: Icebox with ice, 3 empty plastic cups for blood stuffs  
: Water filled beaker, (½ water + ½ bleach) filled beaker 
: 1 ml, 0.4ml, and 0.25ml pipettes 
 
Metabolic gas collecting 
: Blood pressure monitor, heart rate monitor, two master timers, and hose 
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C4. How to take the Study Supplements 
 
1. You will be given two lozenges in a sealed plastic bag each week to take home with you.  Keep the bag sealed and airtight.   
2. The lozenges (tablets) are designed to dissolve in your mouth.  Just suck on the lozenge until it is completely dissolved.  Do 
not chew it.   
3. Take one lozenge when you first wake up two days before your experimental trial and the second lozenge one day before your 
experimental trial.  For example, if you are being tested on Tuesday, you would take one lozenge on Sunday and one on 
Monday.   
4. Do not brush teeth within 30 minutes of taking the lozenge.  It is ok to eat after taking the lozenge.   
5. Do not use mouth wash at anytime during the two weeks you are being tested (starting when we give you your first two 
lozenges) 
6. When you open the plastic bag to remove the first lozenge, make sure you get as much air out of the bag before resealing it.   
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C5. Quick Manual of FAM, T1, and T2 
 
Time Procedures 
 
 
 
- 20 min 
□ Check-in Time____: ____ AM / PM 
□ Check no caffeine for 12h and no strenuous exercise and no alcohol for 24h with enough water during fasting  
□ Record time of last meal ____: ____ AM / PM 
□ Check no mouthwash in the morning, Brushing teeth (No, Yes)____: ____ AM / PM 
□ Have subject use restroom at 9thfloor □ Check subject’s body mass _____lb._____Kg at 8th floor 
□ Ask subject to drink water (800ml -> _____ ml) and explain no water will be served till end of the test 
□ Check blood glucose _____mg/dl□ Verifying heart rates monitor (Tech 1) 
□ Catheter insertion→ □ BD1→ □ Flush each 6 – 7 min by using small timer (Lead), 2min break□ BP1____ /____ mmHg (Tech 1) 
Pre-Treatment Resting Baseline 
-10min 
 
□ Have subject sit in Biodex □ 5min baseline gas collection, HR_____ bpm at 3 min (Tech 1) 
□ Generate report summary: Name – FAM, T1, or T2 – Pre treatment resting– Beet Elite TM 
- 4 min □ Have subject move to the chair□ Have subject take study product and finish it 
Post-Treatment Resting Baseline 
  0 min □Start master timers00:00, Pre-set position and ROM 0 – 90 degree (Max GET) 
27 min □ Have subject sit in Biodex and prepare for gas analysis (Tech 1) 
30 min □ Start metabolic cart, HR_____ bpm at 3 min (Tech 1) 
35 min □ Pause metabolic cart at 05:00 min(Tech 1) □ BD 2 →□ BP 2 ____ /____  mmHg (Tech 1) 
~ 40 min □ Set Biodex position, waist belt, chest belt, leg belt, ankle adaptor 
Post-Treatment Exercise / Recovery 
At 05:10 
Of MC 
□ Resume metabolic cart at 05:00 of MC 
□ Start 1st set at 05:10 until 4th set of Biodex exercise  
□Record master timer ___: ___ (Tech 1) 
MC timer 1st end ___: ___ (Tech 1) 
MC timer 2
nd
 end ___: ___ (Tech 1) 
MC timer 3
rd
 end ___: ___ (Tech 1) 
MC timer 4
th
 end ___: ___ (Tech 1) 
HR 1_____bpm 
HR 2_____bpm 
HR 3_____bpm 
HR 4_____bpm 
 □ BD 3→ □ BP 3____ /____  mmHg (Tech 1), Recovery HR measurement: 15 sec before every single kick 
 □ Start 5th set and keep to the end of Biodex exercise  
□ MC timer 5th start  ___: ___ (Tech 1) 
□ MC timer 10th end  ___: ___ (Tech 1) 
HR 5_____bpmHR 8_____bpm 
HR 6_____bpm    HR 9_____bpm 
HR 7_____bpmHR 10_____ bpm 
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   Comments:                                                                                                                                                                                          BD5 time:  
 
At 22:00 
Of MC 
□ BD 4 □ Stop metabolic cart at 22:00 (Tech 1) □ Record master timer ___: ___ (Tech 1) 
□Remove head gear set →have subject sit in the chair →□HR 11_____ bpm, □BP 4 ____ /____  mmHg (Tech 1) 
□ Generate report summary: Name – FAM, T1, or T2 – Post treatment  – Beet Elite TM 
 □ Give subject water □ Give subject 2 lozenges of placebo or treatment for next visit 
□ Explain the administration method and precautions for 2 days prior to their appointment  
□ Give subject beverage and 1 or 2 energy bar 
□ Print out food logs and exercise logs at 818 
 □ Check-out Time____: ____ AM / PM 
□ Tidy up 902, clean everything, place everything in its place 
□Prepare stuffs for next experiment, and confirm with Trial protocol 
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